

---

## Introduction

This report presents summary tables and figures about Wisconsin cancer incidence and mortality in 1995. The source of the incidence data is the Wisconsin Cancer Reporting System, maintained by the Center for Health Statistics in the Division of Health, and includes all 1995 reports received by May 1997. The mortality data are from death certificates for Wisconsin residents, also maintained by the Center for Health Statistics.

The need for accurate information about cancer incidence was formally recognized by the Wisconsin Legislature when it declared cancer to be a reportable disease in 1932. Reportable cancers are all malignant *in situ* (noninvasive) and invasive neoplasms except basal cell carcinoma and squamous cell carcinoma that arise in the skin. In July 1976, the State Division of Health with the Wisconsin Clinical Cancer Center began the population-based Cancer Reporting System, collecting data in southeast Wisconsin. In 1978, the system was expanded to include information from all acute-care general medical-surgical hospitals in Wisconsin. In 1992, clinics unaffiliated with any hospital and independent physicians that provide cancer-directed treatment began reporting cancer cases. Additional data sources have also been added over the years to meet the changing patterns of cancer care as it became more decentralized from hospital inpatient care. Please refer to the Technical Notes, pages 39-56, for data collection procedures, definitions, and modifications that describe the 1995 cancer data.

Special recognition is given to the Wisconsin hospitals, clinics and physicians participating in the Cancer Reporting System. Without their cooperation, much of the report would not be possible. Recognition is also given to the nearby Minnesota hospitals, the State Health Registry of Iowa, the Michigan Department of Health, the Illinois Department of Public Health, the California Department of Health Services, the Indiana State Cancer Registry, the Missouri Cancer Registry, the Texas Department of Health, the Wyoming Central Tumor Registry, the Mississippi State Department of Health and the Colorado Central Cancer Registry for the case reports of Wisconsin residents who receive care in those states.

Requests for additional cancer incidence data may be addressed to:

Laura Stephenson-Vine  
Cancer Reporting System  
Wisconsin Division of Health  
P.O. Box 309, Room 172  
Madison, WI 53701-0309



---

## Key Findings

- C The number of new reportable cancer cases diagnosed in 1995 for Wisconsin residents was 24,607 (compared with 23,711 in 1994).
- C In 1995, the most frequently reported cancers among Wisconsin women were breast (31%), lung (10%), and colon (10%). For Wisconsin men, the most frequently reported cancers were prostate (28%), lung (15%) and colon (9%).
- C The overall age-adjusted cancer incidence rate for Wisconsin residents in 1995 was 405 per 100,000 population. For males it was 449 per 100,000 population, and for females it was 380 per 100,000 population. While the cancer incidence rate for males is virtually the same as reported in 1994, the rate for females is higher than the 359 per 100,000 reported in 1994. Reported breast cancer cases accounted for the largest portion of the increase.
- C The age-adjusted rate for reported female breast cancer cases increased from 111 per 100,000 population in 1994 to 122 per 100,000 population in 1995 (see Modifications Affecting 1995 Data in the Technical Notes on page 43 for factors that may have contributed to the increase).
- C While the age-adjusted incidence rate for female breast cancer increased in 1995, the age-adjusted mortality rate decreased slightly (24.0 per 100,000 population as compared to 25.7 in 1994).
- C More reported breast cancers were diagnosed at the earliest stage of disease (*in situ*) in 1995; 13 percent in 1995 compared to 10 percent in 1994 (see Technical Notes on page 44 for a definition of *in situ*).
- C The reported incidence of female breast cancer increases from 259 cases in the 40-44-year age group to 503 cases in the 70-74-year age group. The reported incidence of prostate cancer increases from 247 cases in the 55-59-year age group to 745 cases in the 70-74-year age group. Most cancers are age-related; incidence rises with increasing age (see Figures 1 and 2).
- C Persons aged 60 or older accounted for 70 percent of newly diagnosed reportable cancer cases and 74 percent of reportable cancer deaths.
- C Seventy-eight percent of all newly diagnosed cancer cases received cancer-directed treatment (treatments that remove or destroy cancer tissue). Forty percent of reported cancer cases received only surgical treatment.
- C The number of Wisconsin residents who died of a reportable cancer in 1995 was 10,521 (compared to 10,375 in 1994).

- 
- C The overall age-adjusted cancer mortality rate for Wisconsin residents in 1995 was 161 per 100,000 population. For males it was 200 per 100,000 population, and for females it was 133 per 100,000 population. These are similar to the 1994 rates (196 for males and 137 for females, per 100,000 population).
  - C The highest rates of cancer deaths among Wisconsin women were lung (28 per 100,000 population), breast (24 per 100,000), and colon (12 per 100,000). For Wisconsin men, the highest rates of cancer deaths were lung (58 per 100,000 population), prostate (26 per 100,000) and colon (17 per 100,000).
  - C Forty-six months is the average months-to-death from the time of diagnosis for cancers that were initially diagnosed with *in situ* or localized stage of disease, compared to 32 months for cancers diagnosed with regional stage and 14 months for cases diagnosed with distant stage.

---

## Overview of Tables

**Demographic characteristics of cancer incidence.** Tables 1-8 present data on the incidence of cancer diagnosed among Wisconsin residents. Table 1 lists cancer incidence by *individual* primary site (the organ of origin), Tables 2, 3, 5 and 8 list incidence by *site group*, and Tables 4, 6 and 7 list incidence by *major site group*. Classification of site and site groups is from the International Classification of Diseases for Oncology, Second Edition. Tables 2, 4 and 6 present data using age-adjusted rates while Figure 1 uses age-specific rates. These tables and the figure highlight differences in the incidence of cancer by selected demographic variables collected by the Cancer Reporting System (sex, race, residence and age).

Table 1.	Reported Cancer Cases by Individual Primary Site and Sex . . . . .	7
Table 2.	Age-Adjusted Rate of Reported Cancer Cases by Site Group and Sex . .	8
Table 3.	Reported Cancer Cases by Site Group, Race and Sex . . . . .	9
Table 4.	Age-Adjusted Rate of Reported Cancer Cases by Major Site Group and Region . . . . .	10
Table 5.	Reported Cancer Cases by Site Group and County of Residence . . . . .	11
Table 6.	Age-Adjusted Rate of Reported Cancer Cases by Major Site Group, Selected Counties . . . . .	14
Table 7.	Reported Cancer Cases for Major Cities and the Surrounding Counties	15
Table 8.	Reported Cancer Cases by Site Group, Age and Sex . . . . .	16
Figure 1.	Age-Specific Cancer Incidence Rate . . . . .	18

**Tumor characteristics.** Tables 9-11 focus on three characteristics of cancer tumors: type of diagnostic confirmation, stage of disease at the time of diagnosis and tumor cell type. These characteristics aid in assessing prognosis and planning treatment.

Table 9.	Reported Cancer Cases by Site Group and Type of Diagnostic Confirmation . . . . .	19
Table 10.	Reported Cancer Cases by Site Group and Stage of Disease . . . . .	20
Table 11.	Reported Cancer Cases by Site Group and Tumor Cell Type . . . . .	21

**Treatment.** Tables 12 and 13 present data on treatment modalities (type of treatment) for cancers diagnosed in 1995. This information is separated into three categories: definitive therapy (treatment that removes or destroys cancer tissue for prolongation of life), nondefinitive therapy (treatment given to improve patient function and comfort) and no treatment reported. Many cancers receive more than one type of treatment so there are often multiple treatment reports for each tumor. Tables 12 and 13 approximate the planned course of definitive treatment for each newly diagnosed tumor in 1995. The data in these tables are compiled from cumulative reports received by May 1997.

Table 12.	Treatment Modality by Site Group . . . . .	22
Table 13.	Selected Treatment Modalities for Selected Site Groups by Stage of Disease . . . . .	23

**Cancer mortality.** Tables 14-21 and Figures 2-5 present data on Wisconsin residents who died from a reportable cancer in 1995 (deaths from certain skin cancers are excluded because they are non-reportable). Tables 14-18 and Figures 2-5 highlight differences in cancer mortality by demographic characteristics (sex, age, race and residence). Tables 19-21 show the average months to death from the time of diagnosis, by site group, for age at diagnosis, stage of disease and usual occupation. These three tables were created from 1995 reportable cancer deaths that were linked to an existing cancer incidence report (initially diagnosed since 1978) on file with the Cancer Reporting System.

Table 14.	Age-Adjusted Rate of Cancer Mortality by Site Group and Sex . . . . .	24
Table 15.	Cancer Mortality by Site Group, Race and Sex . . . . .	25
Table 16.	Age-Adjusted Rate of Cancer Mortality by Site Group and Region . . . .	26
Table 17.	Reportable Cancer Deaths by Site Group and County of Residence . . .	27
Table 18.	Cancer Mortality by Race, Sex and Age . . . . .	30
Table 19.	Cases Linked to Reportable Cancer Deaths by Age at Diagnosis . . . . .	31
Table 20.	Cases Linked to Reportable Cancer Deaths by Stage of Disease at Diagnosis . . . . .	32
Table 21.	Cases Linked to Reportable Cancer Deaths by Usual Occupation . . . . .	33
Figure 2.	Age-Specific Cancer Mortality Rate . . . . .	34
Figure 3.	Cancer Incidence and Mortality by Site and Sex . . . . .	35
Figure 4.	Average Years of Potential Life Lost Due to Cancer: Males . . . . .	36
Figure 5.	Average Years of Potential Life Lost Due to Cancer: Females . . . . .	37

**Technical Notes.** This section provides information on the Wisconsin Cancer Reporting System and definitions for variables used in this report.

Cancer Reporting Statute and Administrative Rules . . . . .	39
Neoplasm Report Form . . . . .	40
Operating Procedures . . . . .	41
Modifications Affecting 1995 Data . . . . .	43
Patient Residence . . . . .	43
Patient Race . . . . .	44
Stage of Disease . . . . .	44
Type of Diagnostic Confirmation . . . . .	44
Treatment Modality . . . . .	45
Incidence/Death Case Matching . . . . .	46
Years of Life Lost . . . . .	46
Comparing Cancer Data . . . . .	46
Supplemental Data Sources . . . . .	47
Coding of Reported Cases . . . . .	48
Coding of Mortality . . . . .	52
Wisconsin Population Estimates . . . . .	53
Department of Health and Family Services Regional Map . . . . .	55
Cancer Incidence Update for 1993 Diagnoses . . . . .	56

**Table 1. Reported Cancer Cases by Individual Primary Site and Sex**

PRIMARY SITE	MALE		FEMALE		TOTAL	
	Number	%	Number	%	Number	%
Lip	63	0.5	8	0.1	71	0.3
Tongue	63	0.5	49	0.4	112	0.5
Major Salivary Glands	41	0.3	29	0.2	70	0.3
Gum	7	0.1	10	0.1	17	0.2
Floor of Mouth	35	0.3	22	0.2	57	0.2
Other & Unspecified Parts of Mouth	51	0.4	35	0.3	86	0.3
Oropharynx	50	0.4	27	0.2	77	0.3
Nasopharynx	10	0.1	5	0.0	15	0.1
Hypopharynx	51	0.4	15	0.1	66	0.3
Other Sites in Lip, Oral Cavity & Pharynx	12	0.1	6	0.0	18	0.1
Esophagus	218	1.8	77	0.6	295	1.2
Stomach	275	2.3	153	1.2	428	1.7
Small Intestine	51	0.4	40	0.3	91	0.4
Colon	1,121	9.3	1,211	9.7	2,332	9.5
Rectum, Rectosigmoid Junction & Anus	484	4.0	376	3.0	860	3.5
Liver & Intrahepatic Bile Duct	117	1.0	66	0.5	183	0.7
Gallbladder & Extrahepatic Bile Duct	48	0.4	91	0.7	139	0.6
Pancreas	259	2.1	262	2.1	521	2.1
Retroperitoneum & Peritoneum	6	0	17	0.1	23	0.1
Other Within Digestive Organs & Peritoneum	9	0.1	6	0.0	15	0.1
Nasal Cavities & Sinuses, Internal Ear	27	0.2	12	0.1	39	0.2
Larynx	198	1.6	58	0.5	256	1.0
Trachea, Bronchus & Lung	1,823	15.1	1,245	10.0	3,068	12.5
Pleura	51	0.4	15	0.1	66	0.3
Thymus, Heart & Mediastinum	14	0.1	12	0.1	26	0.1
Other Respiratory & Intrathoracic Sites	0.0	0.0	0.0	0.0	0.0	0.0
Hematopoietic & Reticuloendothelial Systems, Except Leukemia	153	1.3	116	0.9	269	1.1
Bone, Joints & Articular Cartilage	47	0.4	41	0.3	88	0.4
Connective, Subcutaneous & Other Soft Tissue	134	1.1	94	0.8	228	0.9
Melanoma of Skin	397	3.3	294	2.4	691	2.8
Breast	38	0.3	3,884	31.1	3,922	15.9
Uterus, NOS	-	-	27	0.2	27	0.1
Cervix Uteri	-	-	907	7.3	907	3.7
Placenta	-	-	1	0.0	1	0.0
Corpus Uteri	-	-	705	5.6	705	2.9
Ovary, Fallopian Tube & Broad Ligamen	-	-	472	3.8	472	1.9
Other & Unspecified Female Genital Organs	-	-	138	1.1	138	0.6
Prostate	3,430	28.3	-	-	3,430	13.9
Testis	173	1.4	-	-	173	0.7
Penis & Other Male Genital Organs	38	0.3	-	-	38	0.2
Urinary Bladder	798	6.6	290	2.3	1,088	4.4
Kidney & Other Urinary Organs	403	3.3	263	2.1	666	2.7
Eye & Lacrimal Gland	27	0.2	25	0.2	52	0.2
Brain	189	1.6	149	1.2	338	1.4
Other & Unspecified Parts of Nervous System	17	0.1	20	0.2	37	0.2
Thyroid Gland	74	0.6	187	1.5	261	1.1
Other Endocrine Glands	8	0.1	7	0.1	15	0.1
Lymph Nodes	353	2.9	340	2.7	693	2.8
Hodgkin's Disease	71	0.6	63	0.5	134	0.5
Lymphoid Leukemia	181	1.5	123	1.0	304	1.2
Myeloid Leukemia	129	1.1	118	0.9	247	1.0
Other Leukemia	52	0.4	43	0.3	95	0.4
Other & Ill-defined Sites	57	0.5	61	0.5	118	0.5
Unknown Primary Site	259	2.1	280	2.2	539	2.2
All Reportable Sites	12,112	100.0	12,495	100.0	24,607	100.0

- C The primary site of a tumor is the organ of origin. Primary site affects prognosis by its accessibility for treatment, proximity to other organs, and the physiological role of the affected organ.

**Table 2. Age-Adjusted Rate of Reported Cancer Cases by Site Group and Sex**

PRIMARY SITE	MALE		FEMALE		TOTAL	
	Number	Rate	Number	Rate	Number	Rate
Mouth & Pharynx	383	14.5	206	6.5	589	10.2
Stomach	275	10.1	153	3.8	428	6.6
Colon	1,121	40.9	1,211	31.5	2,332	35.6
Rectum & Rectosigmoid Junction	484	18.3	376	10.7	860	14.2
Pancreas	259	9.5	262	7.1	521	8.2
Other Gastro-intestinal Tract	449	16.8	297	8.2	746	12.2
Trachea, Bronchus & Lung	1,823	68.2	1,245	38.1	3,068	51.2
Other Respiratory	290	11.1	97	3.1	387	6.7
Bone & Connective Tissue	179	6.5	134	4.5	313	5.4
Melanoma of Skin	397	14.4	294	9.6	691	11.7
Breast	38	1.4	3,884	122.2	3,922	65.8
Cervix Uteri	-	-	907	31.1	907	15.7
Corpus Uteri	-	-	705	23.0	705	12.2
Other Female Genital	-	-	638	19.6	638	10.5
Prostate	3,430	127.7	-	-	3,430	56.3
Other Male Genital	211	7.2	-	-	211	3.5
Urinary Bladder	798	28.9	290	8.0	1,088	16.9
Kidney & Other Urinary	403	15.0	263	7.6	666	10.9
Eye, Brain & Other Nervous System	233	8.9	194	6.2	427	7.5
Lymph Nodes	424	15.7	403	12.1	827	13.8
Leukemia	362	13.7	284	8.6	646	10.9
All Others	553	20.4	652	18.7	1,205	19.2
All Reportable Sites	12,112	449.3	12,495	380.1	24,607	405.2

Notes: Rates are per 100,000 residents age-adjusted to the 1970 United States population. See Technical Notes on pages 46-47 for explanation about use of age-adjusted rates.

Site groups are listed in ICD-O2 numerical code order.

See Technical Notes on pages 48-50 for the individual sites included in each site group.

- C The overall age-adjusted cancer incidence rate for all reportable sites increased from 393 per 100,000 population in 1994 to 405 per 100,000 population in 1995. The most noticeable changes occurred in female breast cancer (increased from 111 to 122 per 100,000 population), melanoma of skin (male rate increased from 11 to 14 per 100,000 population) and prostate cancer (decreased from 135 to 128 per 100,000 population).

**Table 3. Reported Cancer Cases by Site Group, Race and Sex**

PRIMARY SITE	WHITE						AFRICAN AMERICAN					
	Male		Female		Total		Male		Female		Total	
	Number	%	Number	%	Number	%	Number	%	Number	%	Number	%
Mouth & Pharynx	364	3	195	2	559	2	12	3	5	1	17	2
Stomach	259	2	139	1	398	2	13	3	10	3	23	3
Colon	1,070	9	1,158	10	2,228	10	29	8	27	8	56	8
Rectum & Rectosigmoid Junction	458	4	359	3	817	4	10	3	11	3	21	3
Pancreas	239	2	252	2	491	2	12	3	7	2	19	3
Other Gastro-intestinal Tract	418	4	285	2	703	3	24	6	9	3	33	4
Trachea, Bronchus & Lung	1,705	15	1,182	10	2,887	12	84	22	44	12	128	17
Other Respiratory	279	2	86	1	365	2	9	2	7	2	16	2
Bone & Connective Tissue	169	1	126	1	295	1	7	2	5	1	12	2
Melanoma of Skin	377	3	284	2	661	3	0	0	1	<1	1	<1
Breast	34	<1	3,695	31	3,729	16	3	1	107	30	110	15
Cervix Uteri	-	-	810	7	810	3	-	-	46	13	46	6
Corpus Uteri	-	-	687	6	687	3	-	-	12	3	12	2
Other Female Genital	-	-	609	5	609	3	-	-	16	4	16	2
Prostate	3,227	28	-	-	3,227	14	118	31	-	-	118	16
Other Male Genital	205	2	-	-	205	1	3	1	-	-	3	<1
Urinary Bladder	775	7	281	2	1,056	5	8	2	3	1	11	1
Kidney & Other Urinary	383	3	246	2	629	3	9	2	6	2	15	2
Eye, Brain & Other Nervous System	228	2	187	2	415	2	4	1	6	2	10	1
Lymph Nodes	407	4	386	3	793	3	8	2	8	2	16	2
Leukemia	347	3	263	2	610	3	8	2	7	2	15	2
All Others	518	5	613	5	1,131	5	22	6	21	6	43	6
All Reportable Sites	11,462	100%	11,843	100%	23,305	100%	383	100%	358	100%	741	100%

Notes: Percents are calculated from the total number of cases for the particular sex and race.

Table does not include 244 additional cancer cases diagnosed among persons of races other than white or African American (93 for Native Americans, 89 for Asian/Pacific Islanders and 62 in the category of 'other, not specified'). Exclusion of these cases is due to small numbers and race/ethnicity coding inconsistencies in reporting facilities for non-white, non-African American races (see Technical Notes on page 44).

See Technical Notes on pages 48-50 for the individual sites included in each site group.

- C Prostate cancer was the most frequently reported cancer for both white and African American men and breast cancer was the most frequently reported cancer for both white and African American women.

**Table 4. Age-Adjusted Rate of Reported Cancer Cases by Major Site Group and Region**

PRIMARY SITE	REGION											
	SOUTH		SOUTHEAST		NORTHEAST		WEST		NORTH		TOTAL	
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Colorectal	524	48.0	1,186	51.1	735	51.6	457	50.4	290	43.2	3,192	49.8
Other Gastro-intestinal Tract	334	32.0	934	41.7	474	35.1	289	32.3	253	40.0	2,284	37.1
Respiratory	558	55.1	1,364	63.0	717	54.5	434	50.3	382	61.9	3,455	57.9
Breast	664	64.2	1,550	70.3	853	65.1	514	62.1	341	58.3	3,922	65.8
Female Genital	373	35.9	763	34.8	541	42.8	332	40.6	241	45.1	2,250	38.4
Male Genital	579	56.7	1,360	61.9	824	60.3	470	53.9	408	64.0	3,641	59.8
Urinary Tract	271	25.5	628	27.9	421	29.4	243	27.2	191	29.0	1,754	27.8
Leukemia & Lymph Nodes	265	25.5	536	24.8	325	24.7	172	20.2	175	29.3	1,473	24.7
All Others	485	46.6	929	42.1	572	43.1	366	43.0	284	48.3	2,636	43.8
All Reportable Sites	4,053	389.4	9,250	417.5	5,462	406.6	3,277	380.0	2,565	419.1	24,607	405.2

Notes: Rates are per 100,000 residents, age-adjusted to the 1970 United States population. See Technical Notes on pages 46-47 for explanation about use of age-adjusted rates.

The regions used are the Department of Health and Family Services Regions. See Map on page 55 for regional boundaries.

See Technical Notes on pages 48-50 for the individual sites included in each major site group.

In this table, the major site group "Other Gastrointestinal Tract" also includes the site group "Mouth and Pharynx."

C As in 1993 and 1994, the North and the Southeast regions had the highest reported age-adjusted incidence rate in 1995.

## Demographics of Cancer Incidence

**Table 5. Reported Cancer Cases by Site Group and County of Residence**

RESIDENCE COUNTY	A	A	B	B	B	B	B	C	C	C	C	C	D	D	D	D	D	E	F	F	F	G	G	G	I
	D	S	A	A	R	U	U	A	H	L	O	R	A	O	O	O	U	A	L	O	O	R	R	R	O
	A	H	R	Y	O	F	R	L	I	A	L	A	N	D	O	U	N	U	O	N	R	A	E	E	W
	M	L	R	F	W	F	N	U	P	R	U	W	E	G	R	G	N		R	D	E	N	E	E	A
	S	A	O	I	N	A	E	M	P	K	M	F		E		L		C	E		S	T	N	N	
		N	N	E		L	T	E	E		B	O				A		L	N	D	T				
		D		L		O	T	T	W		I	R				S		A	C	U				L	
			D					A			A	D						I	E					A	
																		R		L				K	
																		E		A				E	
PRIMARY SITE																									
Mouth &																									
Pharynx	2	3	5	2	17	3	0	2	7	3	6	2	39	5	6	2	3	4	1	12	0	10	2	4	2
Stomach	1	5	2	1	20	1	3	1	5	5	2	2	23	5	2	4	3	7	1	10	1	3	3	1	1
Colon	7	16	21	5	92	6	9	10	27	16	20	4	143	31	21	28	10	42	0	58	3	16	19	7	16
Rectum & Rectosigmoid																									
Junction	3	2	7	5	40	3	2	5	9	9	12	2	51	9	14	4	6	13	1	29	4	14	4	4	6
Pancreas	0	1	4	0	20	1	0	3	6	3	5	2	28	12	4	4	3	7	1	12	3	2	3	2	2
Other Gastro-intestinal																									
Tract	3	1	7	2	34	4	3	5	7	3	8	1	44	9	4	6	5	8	1	5	1	5	5	5	4
Trachea, Bronchus &																									
Lung	14	12	25	8	96	6	18	10	33	19	32	10	173	49	18	30	8	52	4	53	10	29	16	17	6
Other																									
Respiratory	1	1	3	2	17	0	3	1	3	0	6	0	15	10	3	4	1	4	0	11	0	2	4	4	2
Bone & Connective																									
Tissue	0	1	4	1	14	0	0	0	3	1	1	1	26	3	4	5	2	6	0	8	0	6	1	4	1
Melanoma of																									
Skin	4	5	6	2	26	2	2	5	4	20	7	2	84	8	4	4	2	2	0	16	0	6	11	1	1
Breast	7	15	23	15	161	13	10	17	43	43	48	10	279	47	23	38	22	62	7	86	4	52	23	24	17
Cervix Uteri	5	2	9	1	31	2	2	5	8	10	6	9	55	14	1	2	1	8	0	61	5	10	8	5	2
Corpus Uteri	2	1	3	4	33	2	2	5	10	5	10	3	41	8	9	6	1	13	3	21	2	5	4	2	5
Other Female																									
Genital	2	1	2	1	18	5	2	1	5	4	4	1	53	7	5	3	6	10	1	13	3	6	6	3	5
Prostate	13	14	40	10	139	7	10	10	35	33	37	14	200	46	33	16	12	54	3	66	10	36	22	12	24
Other Male																									
Genital	0	0	1	2	10	0	0	1	2	0	0	2	15	1	0	1	0	2	0	5	0	5	2	0	0
Urinary																									
Bladder	6	5	9	1	45	5	5	4	14	10	9	4	59	15	13	8	6	22	0	25	2	14	13	6	1
Kidney & Other																									
Urinary	4	4	4	3	30	4	1	4	8	4	6	2	40	9	7	5	4	14	0	16	0	3	4	3	0
Eye, Brain & Other Nervous																									
System	2	1	2	0	12	2	0	3	9	4	5	2	33	11	8	3	2	1	0	9	0	5	4	4	2
Lymph Nodes	5	6	5	2	30	1	3	4	9	7	13	4	62	13	4	6	3	15	1	16	1	7	6	6	3
Leukemia	6	2	8	2	28	1	2	4	7	4	8	4	40	12	7	3	1	3	0	16	3	3	3	2	0
All Others	3	2	9	3	38	4	6	5	13	11	15	2	81	21	5	3	11	17	1	22	0	14	6	8	7
All Reportable																									
Sites	90	100	199	72	951	72	83	105	267	214	260	83	1,584	345	195	185	112	366	25	570	52	253	169	124	107

Note: See Technical Notes on pages 48-50 for the individual sites included in each site group.

**Table 5. Reported Cancer Cases by Site Group and County of Residence, Continued**

RESIDENCE COUNTY	J A C I R O N	J E F K S O N	J U N E S A	K E W A C R O E S E	K E W A C R O E S E	L A A C R O E S E	L A A G L O A D E	L A A G L O A D E	L A A G L O A D E	M A N I A I O W C	M A N I A I O W C	M A N I A I O W C	M A N I A I O W C	M A N I A I O W C	M A N I A I O W C	M A N I A I O W C	M A N I A I O W C	O C N I A E O A E	O C N I A E O A E	O C N I A E O A E	O C N I A E O A E	O C N I A E O A E	P E I R K A E E	P E I R K A E E	P E I R K A E E	P E I R K A E E			
PRIMARY SITE																													
Mouth & Pharynx	1	4	5	5	19	2	14	0	3	6	20	12	6	2	1	123	2	6	9	8	10	0	2	4	9				
Stomach	1	3	7	2	12	2	7	1	7	3	9	11	2	0	0	96	1	4	4	6	3	0	0	0	4				
Colon	2	4	27	16	74	11	45	15	9	22	39	46	23	4	4	431	20	20	19	70	23	2	16	13	12				
Rectum & Rectosigmoid Junction	1	3	10	1	20	3	17	4	4	4	8	18	7	4	0	172	3	6	4	19	11	2	2	8	7				
Pancreas	2	2	3	1	9	1	9	1	3	4	6	12	1	1	0	126	6	4	7	9	6	2	0	5	2				
Other Gastro-intestinal Tract	2	7	10	1	20	0	11	2	4	2	13	16	2	1	0	162	7	10	10	21	9	0	5	9	5				
Trachea, Bronchus & Lung	8	9	39	24	72	10	46	10	15	25	38	59	26	12	2	639	16	14	45	88	41	0	18	29	26				
Other Respir- atory	0	1	7	2	13	1	3	1	1	1	8	9	2	1	0	79	1	8	3	10	3	0	3	5	4				
Bone & Connective Tissue	1	2	5	2	7	0	9	0	3	3	4	4	3	1	0	65	2	2	2	7	4	1	1	3	4				
Melanoma of Skin	0	1	4	6	9	1	17	0	1	3	5	14	2	3	0	98	7	6	11	23	8	0	5	1	11				
Breast	8	17	44	26	94	14	65	7	16	24	78	75	21	13	1	774	32	21	28	104	49	3	21	23	17				
Cervix U. Corpus	1	4	7	7	26	0	53	3	3	10	11	25	5	3	2	159	16	6	19	6	5	0	6	7	6				
Uteri	0	2	9	5	16	4	12	2	3	8	16	16	16	2	0	129	6	3	8	16	10	0	2	4	2				
Other Female Genital	0	5	5	6	12	2	9	0	1	2	10	12	5	4	2	111	7	3	8	15	9	2	7	6	3				
Prostate	6	18	33	21	92	16	44	10	18	27	70	63	36	7	3	626	29	30	41	91	53	3	23	22	33				
Other Male Genital	1	1	0	2	3	0	12	1	0	3	5	10	0	0	0	33	2	1	2	2	4	0	0	1	2				
Urinary Bladder	1	3	8	3	26	5	17	2	5	8	19	24	5	5	1	189	10	12	14	21	17	3	5	5	1				
Kidney & Other Urinary	0	1	7	4	13	3	14	0	3	12	11	16	5	1	1	109	7	5	8	21	12	4	2	5	4				
Eye, Brain & Other Nervous System	2	3	2	3	5	1	9	1	1	1	7	11	2	2	1	83	3	3	2	13	4	2	3	0	3				
Lymph Nodes	0	1	11	7	18	4	13	4	3	12	23	29	6	5	0	146	9	3	4	21	14	2	8	7	8				
Leukemia	2	2	6	2	17	3	14	2	5	5	10	19	2	3	0	119	9	5	1	17	9	0	3	3	5				
All Others	3	3	9	7	26	9	29	3	6	14	25	24	10	14	2	239	9	10	17	29	14	2	11	5	9				
All Reportable Sites	42	96	258	153	603	92	469	69	114	199	435	525	187	88	20	4,708	204	182	266	617	318	28	143	165	177				

Note: See Technical Notes on pages 48-50 for the individual sites included in each site group.

**Table 5. Reported Cancer Cases by Site Group and County of Residence, Continued**

Reported Cancer Cases by Site Group and County of Residence, Continued																									
RESIDENCE COUNTY	P R I C E	R A I C N E A	R I C H L A N D	R O C K K	R U S S	S T A T E	S A U T E	S A W A R E O I X	S H A E B O Y G A N	T A Y L O R A L E A U	T R E N E A U	V E R M O N T A N A	V I L A W O O T H A	W A S H I N G T O N	W A S H I N G T O N	W A S H I N G T O N	W A S H I N G T O N	W A S H I N G T O N	W A S H I N G T O N	W A S H I N G T O N	W A S H I N G T O N	S T A T E			
PRIMARY SITE																									
Mouth & Pharynx	4	28	5	9	4	6	7	2	3	15	2	3	4	4	7	1	5	39	6	4	9	7	589		
Stomach	1	24	1	5	0	1	6	5	2	10	1	3	0	3	6	0	6	31	5	3	8	10	428		
Colon	13	65	7	62	7	21	32	9	25	42	4	13	22	20	48	14	51	139	36	13	65	30	2,332		
Rectum & Rectosigmoid Junction	2	31	3	15	1	6	12	2	5	9	2	12	7	6	17	7	15	52	7	7	28	18	860		
Pancreas	2	17	1	15	3	6	4	4	4	12	2	1	7	4	4	1	8	39	5	1	20	11	521		
Other Gastro-intestinal Tract	4	40	2	16	4	5	9	2	4	20	3	5	5	5	6	2	13	41	10	2	25	14	746		
Trachea, Bronchus & Lung	16	116	8	99	8	22	37	17	28	57	12	10	22	22	59	18	48	188	42	12	106	62	3,068		
Other Respiratory	2	17	1	3	1	5	4	0	1	10	0	1	3	7	6	4	5	32	3	1	7	11	387		
Bone & Connective Tissue	0	9	1	4	1	1	1	4	2	7	0	0	2	1	4	2	11	22	2	0	7	5	313		
Melanoma of Skin	1	23	1	7	3	1	12	0	8	18	5	5	4	7	4	5	14	58	3	3	14	35	691		
Breast	22	134	9	99	15	21	40	9	38	80	12	19	27	26	64	17	90	301	30	14	128	63	3,922		
Cervix Uteri	6	17	2	24	2	2	4	3	6	33	2	9	10	6	6	4	13	45	7	5	24	25	907		
Corpus Uteri	1	23	2	17	2	4	8	3	6	16	1	5	5	4	11	1	17	42	9	7	21	9	705		
Other Female Genital	3	30	4	10	4	2	8	1	5	17	3	5	5	8	8	3	13	40	11	3	27	15	638		
Prostate	24	122	12	74	16	19	35	9	27	82	16	27	25	27	49	8	63	240	37	21	103	83	3,430		
Other Male Genital	1	12	1	4	0	1	2	0	3	4	0	1	5	2	3	0	6	21	1	1	8	1	211		
Urinary Bladder	6	40	2	28	5	6	14	4	14	26	2	5	5	9	12	3	26	83	15	5	36	32	1,088		
Kidney & Other Urinary	5	21	0	14	6	7	15	6	3	23	2	4	2	5	15	1	9	41	11	4	16	9	666		
Eye, Brain & Other Nervous System	2	6	1	8	2	2	5	1	6	10	3	1	2	2	10	4	14	32	7	1	5	12	427		
Lymph Nodes	6	28	3	16	2	3	12	1	10	11	5	1	5	4	15	1	5	59	6	4	20	20	827		
Leukemia	3	29	3	19	2	5	8	3	7	18	2	4	0	8	9	0	9	42	9	6	15	13	646		
All Others	4	33	4	34	5	15	10	4	10	27	5	7	13	7	7	3	30	70	11	7	43	20	1,205		
All Reportable Sites	128	865	73	582	93	161	285	89	217	547	84	141	180	187	370	99	471	1,657	273	124	735	505	24,607		

Note: See Technical Notes on pages 48-50 for the individual sites included in each site group.

**Table 6. Age-Adjusted Rate of Reported Cancer Cases by Major Site Group, Selected Counties**

PRIMARY SITE	COUNTY					
	DANE		MILWAUKEE		WAUKESHA	
	Number	Rate	Number	Rate	Number	Rate
Colorectal	194	51.3	603	51.2	191	53.0
Other Gastrointestinal Tract	134	36.4	507	46.5	150	42.0
Respiratory	188	52.9	718	67.5	220	63.5
Breast	279	71.8	774	72.2	301	80.7
Female Genital	149	35.3	399	37.2	127	35.2
Male Genital	215	63.5	659	59.0	261	75.4
Urinary Tract	99	25.2	298	26.0	124	35.2
Leukemia & Lymph Nodes	102	26.6	265	24.9	101	29.1
All Others	224	54.6	485	44.8	182	49.5
All Reportable Sites	1,584	417.5	4,708	429.3	1,657	463.6

Notes: Rates are per 100,000 residents, age-adjusted to the 1970 United States population. See Technical Notes on pages 46-47 for explanation about use of age-adjusted rates.

See Technical Notes on pages 48-50 for the individual sites included in each major site group.

In this table the major site group "Other Gastrointestinal Tract" also includes the site group "Mouth and Pharynx."

The counties selected for this table are the three most populous counties in the state, based on 1995 population estimates. This makes it possible to provide age-adjusted rates.

C The three counties listed in Table 6 all had higher incidence rates than the overall state rate of 405 per 100,000 population.

## Demographics of Cancer Incidence

**Table 7. Reported Cancer Cases by Major Site Group for Major Cities and the Surrounding Counties**

COUNTY Major City	PRIMARY SITE GROUP									Total
	Colo- Rectal	Other GI	Respiratory	Breast	Female Genital	Male Genital	Urinary Tract	Leukemia & Lymph Nodes	Other	
BROWN	132	91	113	161	82	149	75	58	90	951
Green Bay	95	69	94	123	57	108	62	45	70	723
Rest of County	37	22	19	38	25	41	13	13	20	228
DANE	194	134	188	279	149	215	99	102	224	1,584
Madison	103	84	110	174	93	123	56	55	136	934
Rest of County	91	50	78	105	56	92	43	47	88	650
EAU CLAIRE	55	26	56	62	31	56	36	18	26	366
Eau Claire	46	22	49	52	26	46	30	13	20	304
Rest of County	9	4	7	10	5	10	6	5	6	62
KENOSHA	94	60	85	94	54	95	39	35	47	603
Kenosha	80	49	72	80	40	82	33	26	41	503
Rest of County	14	11	13	14	14	13	6	9	6	100
LA CROSSE	62	41	49	65	74	56	31	27	64	469
La Crosse	45	31	29	43	42	33	23	17	43	306
Rest of County	17	10	20	22	32	23	8	10	21	163
MILWAUKEE	603	507	718	774	399	659	298	265	485	4,708
Milwaukee	410	346	483	506	253	423	172	170	300	3,063
Wauwatosa	32	16	34	49	13	40	19	17	26	246
West Allis	36	40	53	51	26	59	26	19	43	353
Rest of County	125	105	148	168	107	137	81	59	116	1,046
OUTAGAMIE	89	44	98	104	37	93	42	38	72	617
Appleton	49	16	64	57	23	48	23	23	39	342
Rest of County	40	28	34	47	14	45	19	15	33	275
RACINE	96	109	133	134	70	134	61	57	71	865
Racine	50	60	77	77	42	73	35	34	45	493
Rest of County	46	49	56	57	28	61	26	23	26	372
ROCK	77	45	102	99	51	78	42	35	53	582
Janesville	31	22	33	37	17	20	18	13	18	209
Rest of County	46	23	69	62	34	58	24	22	35	373
SHEBOYGAN	51	57	67	80	66	86	49	29	62	547
Sheboygan	33	41	45	49	44	46	29	18	34	339
Rest of County	18	16	22	31	22	40	20	11	28	208
WAUKESHA	191	150	220	301	127	261	124	101	182	1,657
Waukesha	48	41	61	77	28	50	27	20	29	381
Rest of County	143	109	159	224	99	211	97	81	153	1,276
WINNEBAGO	93	62	113	128	72	111	52	35	69	735
Oshkosh	59	27	56	72	39	58	21	14	31	377
Rest of County	34	35	57	56	33	53	31	21	38	358

Notes: See Technical Notes on pages 48-50 for individual sites included in each major site group, and page 43 for how city residence was determined.

In this table, the major site group “Other Gastrointestinal Tract” also includes the site group “Mouth and Pharynx.”

Cities selected for this table are those with an estimated 1990 population of at least (or approaching) 50,000.

This table can be used to compare proportionate distributions of primary cancer site groups between a specified city and the county in which it is located.

**Table 8. Reported Cancer Cases by Site Group, Age and Sex**

PRIMARY SITE	AGE AND SEX																				
	ALL AGES			0 - 4		5 - 9		10 - 14		15 - 19		20 - 24		25 - 29		30 - 34		35 - 39		40 - 44	
	Total	M	F	M	F	M	F	M	F	M	F	M	F	M	F	M	F	M	F	M	F
Mouth & Pharynx	589	383	206	0	0	1	1	1	1	1	2	0	1	2	2	5	3	7	3	21	7
Stomach	428	275	153	0	0	0	0	0	0	0	0	2	0	1	0	1	1	3	1	5	3
Colon	2,332	1,121	1,211	0	0	0	0	0	1	0	0	1	2	3	1	7	6	13	10	18	12
Rectum & Recto-sigmoid Junction	860	484	376	1	0	0	0	0	1	1	0	0	0	1	2	7	1	5	5	11	7
Pancreas	521	259	262	0	1	0	0	0	0	0	0	0	0	0	2	1	1	1	0	5	4
Other Gastro-intestinal System	746	449	297	1	2	0	0	0	0	1	0	0	0	0	1	5	3	7	1	19	7
Trachea, Bronchus & Lung	3,068	1,823	1,245	0	0	0	0	0	0	0	0	0	0	2	2	3	4	11	10	23	17
Other Respiratory	387	290	97	1	1	1	0	0	0	0	0	1	1	0	0	0	0	3	2	8	2
Bone & Connective Tissue	313	179	134	5	4	0	3	6	6	3	10	8	4	7	2	8	4	19	5	8	6
Melanoma of Skin	691	397	294	0	0	0	0	0	2	2	4	3	10	14	11	17	20	21	21	31	30
Breast	3,922	38	3,884	0	0	0	0	0	0	0	0	0	3	0	16	0	54	1	136	1	259
Cervix Uteri	907	0	907	0	0	0	0	0	0	0	25	0	122	0	173	0	170	0	125	0	94
Corpus Uteri	705	0	705	0	0	0	0	0	0	0	0	0	1	0	4	0	5	0	12	0	30
Other Female Genital	638	0	638	0	1	0	0	0	2	0	4	0	6	0	9	0	16	0	22	0	40
Prostate	3,430	3,430	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	3	0
Other Male Genital	211	211	0	1	0	0	0	0	0	6	0	11	0	30	0	35	0	27	0	31	0
Urinary Bladder	1,088	798	290	0	0	0	0	0	0	0	0	1	1	0	2	8	2	6	4	7	4
Kidney & Other Urinary	666	403	263	4	2	2	0	1	0	0	0	0	0	2	2	1	5	10	1	22	4
Eye, Brain & Other Nervous System	427	233	194	9	4	4	4	9	1	6	2	5	6	9	8	8	9	10	10	14	8
Lymph Nodes	827	424	403	0	0	4	0	6	5	8	11	10	12	11	12	18	8	22	13	10	10
Leukemia	646	362	284	18	13	12	8	9	4	5	6	1	4	3	3	2	2	8	7	16	10
All Others	1,205	553	652	7	2	1	0	2	1	1	2	3	10	8	25	6	27	14	20	21	37
All Reportable Sites	24,607	12,112	12,495	47	30	25	16	34	24	35	66	46	183	93	277	132	341	189	408	274	591

Note: See Technical Notes on pages 48-50 for the individual sites included in each site group.


## Table 8. Reported Cancer Cases by Site Group, Age and Sex, Continued

PRIMARY SITE	AGE AND SEX																	
	45 - 49		50 - 54		55 - 59		60 - 64		65 - 69		70 - 74		75 - 79		80 - 84		85 +	
	M	F	M	F	M	F	M	F	M	F	M	F	M	F	M	F	M	F
Mouth & Pharynx	16	9	38	19	41	14	54	30	63	25	52	28	47	30	23	17	11	14
Stomach	9	8	19	10	18	9	33	6	38	13	52	13	35	19	35	34	24	36
Colon	29	26	36	52	79	46	127	75	163	155	215	195	179	231	144	211	107	188
Rectum & Recto-sigmoid Junction	17	8	24	25	58	26	75	37	77	54	82	63	63	45	36	52	26	50
Pancreas	13	7	13	14	17	13	32	18	39	38	39	38	47	52	31	35	21	39
Other Gastro-intestinal Tract	18	15	32	11	38	17	56	19	86	44	75	49	54	50	32	41	25	37
Trachea, Bronchus & Lung	57	39	82	72	152	119	238	143	360	214	364	233	276	202	166	118	89	72
Other Respiratory	12	6	19	9	34	8	46	22	49	6	40	12	24	12	34	9	18	7
Bone & Connective Tissue	8	14	10	7	10	8	10	6	19	9	17	9	17	13	14	10	10	14
Melanoma of Skin	32	29	29	19	35	30	34	22	51	28	51	20	42	14	23	14	12	20
Breast	1	353	2	360	5	369	6	411	6	453	7	503	3	435	2	312	4	220
Cervix Uteri	0	53	0	30	0	26	0	23	0	24	0	8	0	6	0	14	0	14
Corpus Uteri	0	57	0	66	0	87	0	94	0	87	0	88	0	95	0	50	0	29
Other Female Genital	0	57	0	39	0	47	0	72	0	66	0	63	0	84	0	65	0	45
Prostate	29	0	123	0	247	0	431	0	717	0	745	0	565	0	338	0	230	0
Other Male Genital	11	0	10	0	7	0	5	0	13	0	14	0	8	0	0	0	2	0
Urinary Bladder	25	2	41	10	45	17	78	33	105	45	151	33	133	48	114	52	84	37
Kidney & Other Urinary	21	9	27	13	40	20	42	23	59	33	59	51	49	42	38	35	26	23
Eye, Brain & Other Nervous System	16	17	10	17	23	10	21	13	23	24	29	17	21	11	12	16	4	17
Lymph Nodes	24	22	31	18	29	19	38	33	51	48	62	60	48	44	34	47	18	41
Leukemia	17	13	11	9	20	12	38	16	50	33	54	33	47	39	34	44	17	28
All Others	20	37	35	30	41	41	61	40	70	72	84	68	75	84	53	71	51	85
All Reportable Sites	375	781	592	830	939	938	1,425	1,136	2,039	1,471	2,192	1,584	1,733	1,556	1,163	1,247	779	1,016

Note: See Technical Notes on pages 48-50 for the individual sites included in each site group.

C The overall age distribution of reported cancer incidence is similar to 1994 figures; 70% of all cancers were diagnosed at age 60 or older compared to 71% in 1994.

Figure 1. Age-Specific Cancer Incidence Rate



- C In general, cancer incidence increases with age. At approximately age 54 the male and female incidence rates intersect, with the female incidence rate being higher prior to age 54 and the male incidence rate climbing higher after age 54.

**Table 9. Reported Cancer Cases by Site Group and Type of Diagnostic Confirmation**

PRIMARY SITE	TYPE OF DIAGNOSTIC CONFIRMATION									
	Positive Histology	Cyto-logy/ Blood	Micro-scopic NOS	Lab Test/ Marker	Surgical Obser- vation	Imaging	Other Clinical Methods	Autopsy	Not Stated	Total
Mouth & Pharynx	565	4	11	0	1	3	3	0	2	589
Stomach	407	3	3	0	2	8	1	0	4	428
Colon	2,219	3	7	4	24	44	4	1	26	2,332
Rectum & Recto- sigmoid Junction	819	3	6	1	11	6	7	0	7	860
Pancreas	360	27	2	2	12	100	5	0	13	521
Other Gastro- intestinal Tract	638	15	31	3	6	28	5	3	17	746
Trachea, Bronchus & Lung	2,456	287	28	3	6	232	12	3	41	3,068
Other Respiratory	363	10	6	0	2	4	0	0	2	387
Bone & Connective Tissue	293	0	9	0	0	4	1	0	6	313
Melanoma of Skin	676	0	10	0	2	0	0	0	3	691
Breast	3,815	11	20	0	14	24	12	1	25	3,922
Cervix Uteri	889	8	4	0	0	0	1	0	5	907
Corpus Uteri	686	7	3	0	0	1	2	1	5	705
Other Female Genital	587	17	6	3	1	19	1	0	4	638
Prostate	3,254	8	13	84	5	13	26	2	25	3,430
Other Male Genital	202	1	1	1	0	0	0	0	6	211
Urinary Bladder	1,041	15	14	1	9	1	2	0	5	1,088
Kidney & Other Urinary	575	16	24	0	1	41	2	0	7	666
Eye, Brain & Other Nervous System	368	2	29	0	3	15	0	0	10	427
Lymph Nodes	777	11	20	2	1	4	1	0	11	827
Leukemia	474	62	71	25	0	0	1	0	13	646
All Others	939	67	34	3	1	109	13	0	39	1,205
All Reportable Sites										
Number	22,403	577	352	132	101	656	99	11	276	24,607
Percent	91.0%	2.3%	1.4%	0.5%	0.4%	2.7%	0.4%	<.1%	1.1%	100%

Notes: Cancers listed under "Microscopic NOS" (not otherwise specified) were diagnosed microscopically but without specification of positive histology or cytology.

See the Technical Notes on page 44 for definitions on the above types of diagnostic confirmation.

Percents may not add to 100 due to rounding.

**Table 10. Reported Cancer Cases by Site Group and Stage of Disease**

	STAGE OF DISEASE									Total
	In Situ	Localized	Direct Extension	Regional Nodes	Direct Extension & Reg Nodes	Regional NOS	Distant	Non-localized NOS	Not Stated	
Mouth & Pharynx	21	257	63	68	76	12	40	4	48	589
Stomach	7	93	41	22	72	23	99	4	67	428
Colon	139	692	418	127	344	54	376	4	178	2,332
Rectum & Rectosigmoid	56	310	126	47	119	18	96	0	88	860
Pancreas	1	75	90	19	45	23	187	2	79	521
Other Gastro-intestinal Tract	11	177	99	35	43	24	188	6	163	746
Trachea, Bronchus & Lung	6	664	209	322	284	89	1,081	0	413	3,068
Other Respiratory	16	179	58	25	26	6	17	3	57	387
Bone & Connective Tissue	3	148	28	4	1	7	54	10	58	313
Melanoma of Skin	193	379	15	8	6	3	22	0	65	691
Breast	528	2,021	95	675	181	35	151	0	236	3,922
Cervix Uteri	675	123	34	6	13	1	9	0	46	907
Corpus Uteri	20	470	70	12	10	16	52	0	55	705
Other Female Genital	57	180	63	13	20	40	200	1	64	638
Prostate	34	2,341	326	28	26	29	209	0	437	3,430
Other Male Genital	9	122	10	23	3	9	21	0	14	211
Urinary Bladder	271	577	91	8	14	13	39	0	75	1,088
Kidney & Other Urinary	23	307	106	5	13	3	151	0	58	666
Eye, Brain & Other Nervous	4	282	49	0	0	14	14	7	57	427
Lymph Nodes	0	152	34	24	8	64	251	287	7	827
Leukemia	0	0	0	0	0	0	0	646	0	646
All Others	5	233	24	47	25	21	389	108	353	1,205
All Reportable Sites										
Number	2,079	9,782	2,049	1,518	1,329	504	3,646	1,082	2,618	24,607
Percent	8.4%	39.8%	8.3%	6.2%	5.4%	2.1%	14.8%	4.4%	10.6%	100%

Notes: NOS stands for Not Otherwise Specified. Nonlocalized NOS is also the default for systemic disease. All leukemias and those lymphomas and other nonsolid tumors with unknown stage of disease are defaulted to Nonlocalized NOS.

See Technical Notes on page 44 for definitions of the stage of disease categories.

See Technical Notes on pages 48-50 for the individual sites included in each major site group.

- C The distribution of *in situ* cancers increased slightly from 7.3% in 1994 to 8.4% in 1995. The largest increases occurred in breast cancer (up from 10% to 13%) and urinary bladder (up from 21% to 25%).

**Table 11. Reported Cancer Cases By Site Group and Tumor Cell Type**

PRIMARY SITE	CELL TYPE GROUP									
	CARCINOMA/ ADENOCARCINOMA		OTHER SOLID		NON-SOLID		UNKNOWN		TOTAL	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Mouth & Pharynx	487	82.6%	55	9.3%	37	6.3%	10	1.7%	589	100%
Stomach	360	84.1	21	4.9	36	8.4	11	2.6	428	100
Colon	2,251	96.5	3	0.0	12	0.5	66	2.8	2,332	100
Rectum & Rectosigmoid Junction	836	97.2	4	0.5	0	0.0	20	2.3	860	100
Pancreas	427	82.0	5	0.1	5	0.1	84	16.1	521	100
Other Gastro-intestinal Tract	640	85.8	23	3.1	35	4.7	48	6.4	746	100
Trachea, Bronchus & Lung	2,782	90.7	54	1.8	9	0.0	223	7.3	3,068	100
Other Respiratory	289	74.7	81	20.9	9	2.3	8	2.1	387	100
Bone & Connective Tissue	9	3	242	77.3	52	16.3	10	3.2	313	100
Melanoma of Skin	0	0.0	691	100.0	0	0.0	0	0.0	691	100
Breast	3,821	97.4	38	1.0	2	<0.1	61	1.6	3,922	100
Cervix Uteri	894	98.6	9	1.0	0	0.0	4	0.4	907	100
Corpus Uteri	627	88.9	72	10.2	1	0.1	5	0.7	705	100
Other Female Genital	538	84.3	67	10.5	1	0.2	32	5.0	638	100
Prostate	3,333	97.2	1	0.0	0	0.0	96	2.8	3,430	100
Other Male Genital	35	16.6	166	78.7	8	3.8	2	1.0	211	100
Urinary Bladder	1,059	97.3	17	1.6	1	0.0	11	1.0	1,088	100
Kidney & Other Urinary	621	93.2	10	1.5	2	0.3	33	5.0	666	100
Eye, Brain & Other Nervous System	11	3.0	371	86.9	31	7.3	14	3.3	427	100
Lymph Nodes	15	2.0	3	0.0	806	97.5	3	0.4	827	100
Leukemia	0	0.0	0	0.0	646	100.0	0	0.0	646	100
All Others	576	47.8	194	16.1	306	25.4	129	10.7	1,205	100
All Reportable Sites	19,611	79.7%	2,127	8.6%	1,999	8.1%	870	3.5%	24,607	100%

Notes: Percents may not add to 100 due to rounding.

See Technical Notes on pages 48-50 for the individual sites included in each site group.

Cell type often determines the nature of tumor growth and its responsiveness to treatment.

- C Tumor cell type is often closely related to the type of tissue in which the tumor originated. Solid tumors such as carcinomas (developing from epithelial cells in the skin or organ surface) and adenocarcinomas (tumors developed from glandular tissue) comprised the majority of cancers reported (80%). Other solid tumors include sarcomas (originating from bone, cartilage, fat, muscle, or other connective tissue), nerve cell and germ cell tumors. Lymphomas, leukemias and plasma cell tumors are nonsolid tumors because they affect cells that circulate throughout the body.

**Table 12. Treatment Modality by Site Group**

PRIMARY SITE	TYPE OF DEFINITIVE TREATMENT									
	Surgical Only		Surgical and Nonsurgical		Nonsurgical Only		No Cancer-Directed Treatment Reported		Total	
	Number	%	Number	%	Number	%	Number	%	Number	%
Mouth & Pharynx	242	41.1%	129	21.9%	139	23.6%	79	13.4%	589	100%
Stomach	167	39.0	45	10.5	68	15.9	148	34.6	428	100
Colon	1,557	66.8	311	13.3	120	5.1	344	14.8	2,332	100
Rectum & Rectosigmoid Junction	417	48.5	212	24.7	108	12.6	123	14.3	860	100
Pancreas	37	7.1	26	5.0	127	24.4	331	63.5	521	100
Other Gastro-intestinal Tract	175	23.5	63	8.4	192	25.7	316	42.4	746	100
Trachea, Bronchus & Lung	461	15.0	207	6.7	1,374	44.8	1,026	33.4	3,068	100
Other Respiratory	66	17.1	89	23.0	135	34.9	97	25.1	387	100
Bone & Connective Tissue	92	29.4	80	25.6	77	24.6	64	20.4	313	100
Melanoma of Skin	594	86.0	19	2.7	13	1.9	65	9.4	691	100
Breast	1,602	40.8	1,699	43.3	313	8.0	308	7.9	3,922	100
Cervix Uteri	693	76.4	37	4.1	56	6.2	121	13.3	907	100
Corpus Uteri	430	61.0	164	23.3	35	5.0	76	10.8	705	100
Other Female Genital	280	43.9	188	29.5	63	9.9	107	16.8	638	100
Prostate	1,348	39.3	257	7.5	974	28.4	851	24.8	3,430	100
Other Male Genital	77	36.5	109	51.7	8	3.8	17	8.1	211	100
Urinary Bladder	787	72.3	158	14.5	40	3.7	103	9.5	1,088	100
Kidney & Other Urinary	406	61.0	46	6.9	68	10.2	146	21.9	666	100
Eye, Brain & Other Nervous System	80	18.7	150	35.1	114	26.7	83	19.4	427	100
Lymph Nodes	64	7.7	73	8.8	431	52.1	259	31.3	827	100
Leukemia	4	0.6	4	0.6	296	45.8	342	52.9	646	100
All Others	189	15.7	160	13.3	347	28.8	509	42.2	1,205	100
All Reportable Sites	9,768	39.7%	4,226	17.2%	5,098	20.7%	5,515	22.4%	24,607	100%

Notes: The category "No Cancer-Directed Treatment Reported" includes cases which received noncancer-directed treatment (for pain management, etc.), cases receiving care out of state for which no treatment information was available, cases for which treatment was refused by the patient, and cases for which treatment was ruled out by the physician.

See Technical Notes on page 45 for definitions of treatment modalities.

See Technical Notes on pages 48-50 for the individual sites included in each site group.

- C The overall distribution of treatment modalities for reported cancer incidence cases was similar to the 1994 distribution with a slight increase in the 'surgery only' category (up from 38.3% in 1994 to 39.7 in 1995) and a slight decrease in the 'non-surgical only' category (down from 22.6% in 1994 to 20.7 in 1995). This change correlates with the increased percentage of *in situ* cancers diagnosed (shown in Table 10) which are primarily treated with surgery as opposed to non-surgical methods.

**Table 13. Selected Treatment Modalities for Selected Site Groups by Stage of Disease**

PRIMARY SITE	NUMBER OF CASES		PERCENT RECEIVING MODE OF TREATMENT BY STAGE OF DISEASE AT DIAGNOSIS							
			Surgery		Radiotherapy		Chemotherapy		Hormone Therapy	
	Local	Nonlocal	Local	Nonlocal	Local	Nonlocal	Local	Nonlocal	Local	Nonlocal
Stomach	71	187	82	74	8	16	21	39	6	3
Colon	759	1,164	99	91	1	4	5	29	0	0
Rectum & Recto-sigmoid Junction	325	372	89	84	20	39	16	45	0	0
Pancreas	27	150	48	30	52	41	59	68	4	2
Trachea, Bronchus & Lung	516	1,382	67	22	34	66	18	46	0	1
Melanoma of Skin	532	46	100	83	0	20	0	15	0	11
Breast	2,404	1,069	95	86	32	29	9	42	18	30
Cervix Uteri	688	56	98	46	3	86	0	29	0	0
Corpus Uteri	462	137	97	90	20	48	0	15	1	7
Prostate	1,864	513	63	64	36	26	0	2	9	30
Urinary Bladder	786	143	98	92	3	20	7	27	0	0
Kidney & Other Urinary	292	191	100	74	1	23	2	20	0	4
Eye, Brain & Other Nervous System	244	65	67	63	70	75	21	35	3	8

Notes: This table excludes cases with no reported cancer-directed therapy and cases for which local/nonlocal stage of disease is not stated.

Percents across may add up to more than 100 as many patients received more than one type of cancer treatment.

Due to the nature of the therapy, some hormone therapy treatments could be recorded instead as chemotherapy.

- C The most frequent type of treatment performed for locally staged cancers was surgery; while radiotherapy, chemotherapy and immunotherapy were most frequently used for non-locally staged cancers.

**Table 14. Age-Adjusted Rate of Cancer Mortality by Site Group and Sex**

PRIMARY SITE	MALE		FEMALE		TOTAL	
	Number	Rate	Number	Rate	Number	Rate
Mouth & Pharynx	89	3.3	53	1.4	142	2.3
Stomach	137	4.9	89	2.0	226	3.3
Colon	480	17.3	519	12.5	999	14.6
Rectum & Rectosigmoid Junction	104	3.8	79	1.9	183	2.7
Pancreas	275	10.1	295	7.3	570	8.6
Other Gastro-intestinal Tract	387	14.3	231	6.1	618	9.7
Trachea, Bronchus & Lung	1,575	58.2	979	28.2	2,554	41.1
Other Respiratory	67	2.4	24	0.8	91	1.5
Bone & Connective Tissue	53	1.9	52	1.6	105	1.7
Melanoma of Skin	89	3.2	51	1.5	140	2.2
Breast	8	-	876	24.0	884	13.4
Cervix Uteri	-	-	67	2.1	67	1.1
Corpus Uteri	-	-	81	2.3	81	1.3
Other Female Genital	-	-	368	10.0	368	5.6
Prostate	757	25.9	-	-	757	10.0
Other Male Genital	13	-	-	-	13	-
Urinary Bladder	188	6.6	71	1.5	259	3.5
Kidney & Other Urinary	143	5.2	105	2.7	248	3.8
Eye, Brain & Other Nervous System	143	5.4	118	3.6	261	4.4
Lymphoma	251	9.1	250	6.7	501	7.7
Leukemia	225	8.0	205	5.3	430	6.4
All Others	550	20.2	474	12.1	1,024	15.6
Total Cancer Deaths	5,534	200.4	4,987	133.4	10,521	160.7

Notes: Rates are per 100,000 residents, age-adjusted to the 1970 United States population. See Technical Notes on pages 46-47 for explanation about use of age-adjusted rates. Rates based on fewer than 20 cases are omitted because they are subject to large random fluctuations.

The category 'Total cancer deaths' contains all reportable cancer deaths except deaths from nonmelanoma skin cancer (see Technical Notes on page 42)

See Technical Notes on pages 48-50 for the individual sites included in each site group.

- C The age-adjusted cancer mortality rate for males increased slightly, from 196.3 per 100,000 population in 1994 to 200.4 in 1995. The female rate decreased slightly (136.7 per 100,000 population in 1994 to 133.4 in 1995). The overall age-adjusted cancer mortality rate remained constant (160.5 in 1994 to 160.7 in 1995).

**Table 15. Cancer Mortality by Site Group, Race and Sex**

PRIMARY SITE	WHITE						AFRICAN AMERICAN						OTHER					
	Male		Female		Total		Male		Female		Total		Male		Female		Total	
	Number	%	Number	%	Number	%	Number	%	Number	%	Number	%	Number	%	Number	%	Number	%
Mouth & Pharynx	86	2	51	1	137	1	2	1	2	1	4	1	1	2	0	0	1	1
Stomach	131	3	82	2	213	2	5	3	6	4	11	3	1	2	1	3	2	3
Colon	467	9	507	11	974	10	8	4	10	7	18	5	5	12	2	7	7	10
Rectum & Rectosigmoid Junction	101	2	78	2	179	2	2	1	1	1	3	1	1	2	0	0	1	1
Pancreas	264	5	286	6	550	5	8	4	9	6	17	5	3	7	0	0	3	4
Other Gastro-intestinal Tract	361	7	224	5	585	6	20	10	7	5	27	8	6	15	0	0	6	8
Trachea, Bronchus & Lung	1,486	28	942	20	2,428	24	78	38	30	20	108	31	11	27	7	23	18	25
Other Respiratory	60	1	21	<1	81	1	7	3	3	2	10	3	0	0	0	0	0	0
Bone & Connective Tissue	50	1	50	1	100	1	2	1	2	1	4	1	1	2	0	0	1	1
Melanoma of Skin	88	2	51	1	139	1	0	0	0	0	0	0	1	2	0	0	1	1
Breast	7	<1	846	18	853	8	1	1	27	18	28	8	0	0	3	10	3	4
Cervix Uteri	-	-	58	1	58	1	-	-	7	5	7	2	-	-	2	7	2	3
Corpus Uteri	-	-	75	2	75	1	-	-	3	2	3	1	-	-	3	10	3	4
Other Female Genital	-	-	361	8	361	4	-	-	6	4	6	2	-	-	1	3	1	1
Prostate	730	14	-	-	730	7	24	12	-	-	24	7	3	7	-	-	3	4
Other Male Genital	13	<1	-	-	13	<1	0	0	-	-	0	0	0	0	-	-	0	0
Urinary Bladder	184	4	69	1	253	3	4	2	2	1	6	2	0	0	0	0	0	0
Kidney & Other Urinary	139	3	103	2	242	2	4	2	2	1	6	2	0	0	0	0	0	0
Eye, Brain & Other Nervous System	142	3	114	2	256	3	1	1	3	2	4	1	0	0	1	3	1	1
Lymphoma	246	5	246	5	492	5	4	2	1	1	5	1	1	2	3	10	4	6
Leukemia	218	4	196	4	414	4	4	2	6	4	10	3	3	7	3	10	6	8
All Others	517	10	449	9	966	10	29	14	20	14	49	14	4	10	5	16	9	12
Total Cancer Deaths	5,290	100%	4,809	100%	10,099	100%	203	100%	147	100%	350	100%	41	100%	31	100%	72	100%

Notes: The category 'Total cancer deaths' contains all reportable cancer deaths except deaths from nonmelanoma skin cancer (see Technical Notes on page 42).

Percents are calculated from the total number of deaths for the particular race category and sex.

See Technical Notes on pages 48-50 for the individual sites included in each site group.

C In all three race categories listed above, lung cancer was the most frequent cause of cancer death.

**Table 16. Age-Adjusted Rate of Reportable Cancer Mortality by Major Site Group and Region**

PRIMARY SITE	REGION											
	SOUTH		SOUTHEAST		NORTHEAST		WEST		NORTH		TOTAL	
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Colorectal	205	17.5	414	16.8	272	17.9	184	19.2	107	15.2	1,182	17.3
Other Gastro- intestinal Tract	219	20.3	610	25.6	328	23.2	232	24.2	167	24.6	1,556	23.8
Respiratory	468	43.9	1,008	45.1	562	40.4	354	40.3	253	39.4	2,645	42.6
Breast	136	12.3	348	14.8	170	11.6	150	14.9	80	11.9	884	13.4
Female Genital	93	8.7	203	8.9	110	7.6	72	7.2	38	5.2	516	8.0
Male Genital	131	10.2	270	10.1	152	9.2	128	11.2	89	11.4	770	10.2
Urinary Tract	84	7.1	188	7.4	103	6.6	57	5.8	75	10.6	507	7.3
Leukemia & Lymph Nodes	174	15.8	355	14.9	181	12.3	127	13.2	94	13.7	931	14.1
All Others	265	24.4	577	25.0	328	22.8	201	21.9	159	24.9	1,530	24.0
Total Cancer Deaths	1,775	160.2	3,973	168.5	2,206	151.8	1,505	157.8	1,062	156.9	10,521	160.7

Notes: Rates are per 100,000 residents, age-adjusted to the 1970 United States population. See Technical Notes on pages 46-47 for explanation about use of age-adjusted rates.

The regions used are the Department of Health and Family Services Regions. See Map on page 55 for regional boundaries.

The category 'Total cancer deaths' contains all reportable cancer deaths except deaths from nonmelanoma skin cancer (see Technical Notes on page 42).

See Technical Notes on pages 48-50 for the individual sites included in each major site group.

In this table, the major site group "Other Gastrointestinal Tract" also includes the site group "Mouth and Pharynx."

- C In each of the past four years (1992 - 1995), the Southeast Region of Wisconsin has had a higher age-adjusted rate of cancer mortality than any other region of the state.

**Table 17. Reportable Cancer Deaths by Site Group and County of Residence**

RESIDENCE COUNTY	A	A	B	B	B	B	B	C	C	C	C	C	D	D	D	D	D	E	F	F	F	G	G	G	I
	D	S	A	A	R	U	U	A	H	L	O	R	A	O	O	O	U	A	L	O	O	R	R	R	O
	A	H	R	Y	O	F	R	L	I	A	L	A	N	D	O	U	N	U	O	N	R	A	E	E	W
	M	L	R	F	W	F	N	U	P	R	U	W	E	G	R	G	N		R	D	E	N	E	E	A
	S	A	O	I	N	A	E	M	P	K	M	F		E		L		C	E		S	T	N	N	
		N	N	E		L	T	E	E		B	O				A		L	N	D	T				
		D		L		O	T	T	W		I	R				S		A	C	U				L	
				D				A			A	D						I	E					A	
																		R		L				K	
																		E		A				E	
																				C					
PRIMARY SITE																									
Mouth &																									
Pharynx	0	4	1	1	2	0	1	1	2	1	2	0	9	1	0	2	3	1	0	4	1	1	0	1	0
Stomach	1	1	2	1	5	0	1	2	4	4	1	0	6	1	0	2	2	2	0	6	2	1	0	1	0
Colon	5	5	8	5	35	1	11	3	17	8	12	4	57	16	9	12	6	15	1	31	1	12	5	6	5
Rectum & Rectosigmoid																									
Junction	2	1	1	2	8	1	1	1	1	2	1	5	8	1	1	1	0	2	0	6	1	0	1	1	0
Pancreas	1	4	5	1	21	3	1	3	3	1	4	1	29	8	3	6	3	10	3	18	0	5	6	0	0
Other Gastro-intestinal																									
Tract	2	1	6	5	15	2	4	5	5	4	7	3	30	9	6	9	4	11	3	8	0	8	2	5	1
Trachea, Bronchus &																									
Lung	24	14	19	8	90	7	12	14	30	11	29	11	132	44	21	25	12	45	3	35	7	37	19	15	12
Other																									
Respiratory	2	1	2	0	3	1	0	1	1	0	1	0	8	2	0	1	0	0	0	1	0	1	0	0	0
Bone & Connective																									
Tissue	0	0	1	0	4	1	0	0	1	0	1	1	6	5	0	2	0	0	0	2	0	1	0	2	0
Melanoma of																									
Skin	0	0	0	2	6	0	1	0	0	0	2	0	12	5	1	3	1	0	0	3	0	1	1	0	0
Breast	5	3	11	6	31	5	5	3	7	8	6	1	61	12	6	16	3	18	1	17	1	4	10	3	4
Cervix Uteri	2	0	0	0	6	0	0	0	1	0	1	0	5	0	0	0	0	1	0	0	1	1	0	0	0
Corpus Uteri	0	0	0	0	5	1	0	0	0	0	2	1	1	0	1	0	0	2	0	2	0	1	0	0	0
Other Female																									
Genital	1	1	2	1	8	4	2	2	8	1	2	1	32	4	3	1	2	6	0	6	2	4	3	2	2
Prostate	2	6	7	1	14	1	2	3	14	8	11	5	35	26	5	12	7	14	4	9	3	9	5	9	2
Other Male																									
Genital	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Urinary																									
Bladder	3	1	3	0	3	1	1	0	3	2	5	1	9	6	2	4	0	7	1	5	0	1	1	1	1
Kidney & Other																									
Urinary	2	2	0	3	3	1	0	3	3	0	4	1	10	8	0	2	2	2	1	2	0	1	0	0	2
Eye, Brain & Other Nervous																									
System	1	0	3	0	6	2	1	0	8	3	0	2	18	3	3	2	0	2	0	2	1	3	2	3	2
Lymph Nodes	1	3	5	1	15	2	1	1	9	3	7	1	23	11	2	5	2	9	0	11	0	6	4	4	2
Leukemia	5	3	7	1	10	1	2	5	7	5	12	3	31	11	3	2	3	5	0	6	2	5	1	3	4
All Others	1	2	8	1	34	4	4	8	12	10	14	3	54	20	11	4	4	14	2	14	1	15	8	5	3
All Reportable Cancer																									
Deaths	60	52	91	39	325	38	50	55	137	71	124	44	576	193	77	111	54	166	19	189	23	117	68	61	40

Note: See Technical Notes on pages 48-50 for the individual sites included in each site group.

Table 17. Reportable Cancer Deaths by Site Group and County of Residence, Continued

RESIDENCE COUNTY	J A	J C	J F	K U	K E	L A	L A	L A	L A	L I	M A	M A	M A	M A	M E	M I	M O	O C	O N	O U	O Z	P E	P I	P O	P O
PRIMARY SITE																									
Mouth & Pharynx	0	0	3	0	3	0	1	0	0	0	1	1	1	0	0	24	1	1	0	6	10	1	1	1	0
Stomach	0	0	2	2	11	2	5	1	3	3	3	4	0	0	0	49	0	2	4	2	3	0	2	1	3
Colon	2	1	11	4	31	5	17	6	6	12	16	13	5	2	2	176	6	7	10	26	8	2	5	10	8
Rectum & Rectosigmoid Junction	0	0	3	0	5	2	9	0	0	1	1	4	2	3	0	34	0	3	3	4	3	1	1	2	0
Pancreas	3	7	5	2	11	2	11	2	5	2	10	10	6	1	0	130	4	9	6	13	6	1	4	6	5
Other Gastro-intestinal Tract	2	5	4	1	22	0	16	1	5	4	14	9	4	4	0	131	3	8	6	14	4	0	4	2	11
Trachea, Bronchus & Lung	6	8	33	21	67	10	40	11	16	14	38	43	25	9	3	531	16	22	27	52	35	4	17	23	23
Bone & Connective Tissue	1	0	1	0	4	0	5	1	1	0	2	3	1	0	0	22	2	0	0	0	1	0	0	0	0
Melanoma of Skin	0	0	2	1	5	0	1	1	0	3	3	5	2	0	0	22	1	0	1	3	2	0	1	2	2
Breast	2	1	9	3	27	4	18	3	7	5	13	16	12	3	0	182	7	12	4	10	21	1	8	10	7
Cervix U. Corpus	0	0	2	0	0	0	2	1	0	0	1	0	0	0	0	12	0	0	0	1	1	0	1	0	0
Uteri	0	1	0	2	2	0	2	2	0	0	5	2	1	1	0	17	1	0	0	2	1	0	1	0	1
Other Female Genital	0	4	7	3	8	0	4	0	0	1	9	8	6	1	1	75	5	0	0	6	4	0	0	7	1
Prostate	3	2	17	5	20	5	15	2	8	6	14	19	7	4	2	130	9	6	4	19	10	1	2	8	11
Other Male Genital	0	0	2	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	2	0	0	0	0
Urinary Bladder	2	1	6	1	11	1	1	1	0	5	3	6	2	3	0	55	1	1	1	3	2	0	1	3	3
Kidney & Other Urinary	1	0	1	1	5	2	1	0	3	3	11	6	1	0	0	53	3	2	4	6	1	1	1	1	4
Eye, Brain & Other Nervous System	0	3	1	1	11	0	6	1	3	1	3	5	5	0	0	42	3	1	2	8	2	0	1	1	3
Lymph Nodes	1	2	5	1	13	3	10	2	4	1	10	15	4	0	1	99	4	0	4	9	11	1	3	2	10
Leukemia	0	2	6	3	7	5	6	1	4	3	7	11	7	0	0	75	2	1	0	7	6	0	3	6	2
All Others	3	6	12	6	22	4	13	8	6	5	19	26	7	6	3	222	13	2	9	28	16	2	4	8	13
All Reportable Cancer																									
Deaths	26	43	132	58	289	45	184	44	72	69	187	207	98	37	12	2,106	81	79	86	221	150	15	60	96	110

Note: See Technical Notes on pages 48-50 for the individual sites included in each site group.

**Table 17. Reportable Cancer Deaths by Site Group and County of Residence, Continued**

RESIDENCE COUNTY	P R	R A	R I	R O	R U	S T	S A	S A	S H	S H	T A	T R	V E	V I	W A	W A	W A	W A	W A	W A	W I	W O	S T
PRIMARY SITE																							S L
Mouth & Pharynx	1	6	1	8	0	0	1	1	1	4	0	3	2	2	1	1	2	10	1	0	4	0	142
Stomach	0	19	0	5	2	0	2	1	2	9	1	1	0	3	5	0	7	14	3	0	3	2	226
Colon	4	35	6	29	3	12	21	3	8	22	4	7	13	1	18	5	15	52	14	2	31	13	999
Rectum & Rectosigmoid Junction	1	6	0	2	0	0	3	0	2	5	1	1	2	1	3	0	6	8	2	0	7	4	183
Pancreas	0	14	2	21	2	7	3	4	6	10	3	2	2	1	7	5	8	32	7	1	21	12	570
Other Gastro-intestinal Tract	1	23	4	17	3	7	7	3	5	12	1	5	6	9	8	3	17	19	9	1	20	9	618
Trachea, Bronchus & Lung	9	81	8	79	9	30	23	13	25	52	14	11	13	11	47	10	39	140	42	18	72	38	2,554
Other Respiratory	0	3	1	2	0	1	0	0	0	0	0	0	1	0	0	1	1	2	0	2	6	0	91
Bone & Connective Tissue	1	3	0	5	0	2	1	0	1	2	0	2	2	1	3	1	1	3	1	2	2	1	105
Melanoma of Skin	3	5	1	3	0	3	1	0	0	3	1	1	2	3	2	0	2	8	0	0	6	1	140
Breast	2	20	4	14	6	8	9	4	5	15	3	8	7	4	14	3	15	60	13	5	18	15	884
Cervix Uteri	0	5	0	3	0	0	1	0	0	1	0	0	1	2	0	1	3	6	1	2	2	0	67
Corpus Uteri	1	4	0	4	0	1	0	0	0	2	0	0	0	2	1	0	0	5	0	0	1	3	81
Other Female Genital	3	14	3	9	1	1	2	3	2	8	1	5	2	2	9	1	6	21	4	3	15	3	368
Prostate	5	21	3	16	2	8	9	5	7	21	1	3	4	3	15	8	12	40	6	1	14	10	757
Other Male Genital	0	0	1	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	13
Urinary Bladder	2	5	2	10	0	0	1	0	3	4	2	1	1	2	4	1	7	17	3	2	11	7	259
Kidney & Other Urinary	2	9	2	8	3	4	3	4	1	9	3	1	0	3	4	1	2	6	5	2	9	4	248
Eye, Brain & Other Nervous System	3	12	1	7	1	2	3	1	2	8	0	0	0	2	5	1	6	16	7	2	8	4	261
Lymph Nodes	0	22	0	12	1	7	5	1	5	9	0	2	0	7	9	2	5	41	7	4	13	6	501
Leukemia	1	15	2	18	1	0	3	2	3	6	3	1	1	0	9	3	5	27	8	1	11	9	430
All Others	7	34	9	25	4	5	6	1	7	21	4	7	1	5	11	4	23	56	18	7	30	20	1,024
All Reportable Cancer Deaths	46	356	50	297	38	98	104	46	86	224	42	61	60	64	175	51	182	583	151	55	304	161	10,521

Note: See Technical Notes on pages 48-50 for the individual sites included in each site group.

**Table 18. Cancer Mortality by Race, Sex and Age**

AGE GROUP								
	0 - 14	15 - 24	25 - 44	45 - 64	65 - 74	75 - 84	85 +	TOTAL
MALES								
White	22	11	152	1,122	1,671	1,619	693	5,290
African American	1	0	15	84	59	31	13	203
Other	1	1	3	15	14	6	1	41
Total Males	24	12	170	1,221	1,744	1,656	707	5,534
FEMALES								
White	25	14	162	977	1,252	1,516	863	4,809
African American	1	1	18	52	37	30	8	147
Other	0	0	5	11	4	8	3	31
Total Females	26	15	185	1,040	1,293	1,554	874	4,987
Total Cancer Deaths	50	27	355	2,261	3,037	3,210	1,581	10,521

Note: The category 'Total cancer deaths' contains all reportable cancer deaths except deaths from nonmelanoma skin cancer (see Technical Notes on page 42).

C The overall age distribution of cancer deaths remained the same as the 1994 overall age distribution (26% of deaths prior to age 65, 74% of deaths at age 65 or older).

**Table 19. Average Months to Death for Cases Diagnosed Since 1978 Linked to a 1995 Reportable Cancer Death by Age at Diagnosis**

PRIMARY SITE/ CAUSE OF DEATH	AGE AT DIAGNOSIS IN YEARS							
	UNDER 65		65 - 74		75 - 84		85 AND OVER	
	Deaths	Months	Deaths	Months	Deaths	Months	Deaths	Months
Mouth & Pharynx	103	48	67	33	41	35	9	-
Stomach	68	13	77	21	69	13	39	7
Colon	214	42	271	33	264	27	111	17
Rectum & Rectosigmoid Junction	100	41	105	38	89	34	44	22
Pancreas	120	8	130	8	142	6	70	4
Other Gastro-intestinal Tract	154	16	163	9	142	9	48	6
Trachea, Bronchus & Lung	755	17	832	12	575	9	120	7
Other Respiratory	50	57	48	32	36	15	11	-
Bone & Connective Tissue	45	32	26	37	21	19	9	-
Melanoma of Skin	57	50	31	37	28	26	3	-
Breast	405	71	235	67	180	44	62	32
Cervix Uteri	59	58	11	-	10	-	9	-
Corpus Uteri	37	48	53	55	38	21	7	-
Other Female Genital	108	42	71	30	85	17	32	12
Prostate	144	71	267	62	270	47	103	27
Other Male Genital	10	-	3	-	2	-	1	-
Urinary Bladder	52	64	93	52	84	42	49	24
Kidney & Other Urinary	83	31	67	31	74	27	28	5
Eye, Brain & Other Nervous System	133	26	70	15	40	8	10	-
Lymph Nodes	140	50	124	30	87	19	32	12
Leukemia	188	37	136	27	174	21	56	18
All Others	159	17	143	10	135	8	76	3
Total	3,184	37	3,023	29	2,586	22	929	14

Notes: This table includes those cancer deaths that occurred among Wisconsin residents in 1995 that matched a reported cancer diagnosis filed with the Wisconsin Cancer Reporting System since 1978. Each tumor is counted separately for persons with multiple tumors.

See Technical Notes on page 46 for the criteria used to determine a match between the incidence and death reports.

Months to death based on fewer than 20 cases per age group are omitted because they are subject to large random fluctuations.

See Technical Notes on pages 48-50 for the individual sites included in each major site group.

- C As age increases, the average number of months to death decreases: from 37 months for cases diagnosed before age 65 to 14 months for cases diagnosed after age 84.

**Table 20. Average Months to Death for Cases Diagnosed Since 1978 Linked to a 1995 Reportable Cancer Death by Stage of Disease**

PRIMARY SITE/ CAUSE OF DEATH	STAGE OF DISEASE							
	IN SITU & LOCAL		REGIONAL		DISTANT		NOT STATED	
	Deaths	Months	Deaths	Months	Deaths	Months	Deaths	Months
Mouth & Pharynx	69	44	98	34	23	25	30	56
Stomach	38	29	108	16	69	5	38	15
Colon	151	55	334	38	268	13	107	23
Rectum & Rectosigmoid Junction	65	62	141	40	78	15	54	22
Pancreas	58	12	150	8	168	4	86	7
Other Gastro-intestinal Tract	114	18	151	13	131	5	111	6
Trachea, Bronchus & Lung	380	23	649	15	958	7	295	13
Other Respiratory	62	47	44	30	9	-	30	23
Bone & Connective Tissue	37	39	20	35	21	9	23	23
Melanoma of Skin	63	45	19	-	21	20	16	-
Breast	274	75	382	65	140	31	86	57
Cervix Uteri	34	68	29	46	12	-	14	-
Corpus Uteri	58	60	29	40	29	11	19	-
Other Female Genital	33	49	76	26	151	24	36	37
Prostate	313	65	126	62	214	37	131	46
Other Male Genital	6	-	6	-	3	-	1	-
Urinary Bladder	169	57	52	34	23	11	34	34
Kidney & Other Urinary	66	47	68	29	93	9	25	31
Eye, Brain & Other Nervous System	168	19	38	20	7	-	40	20
Lymph Nodes	47	35	57	40	151	28	128	36
Leukemia	-	-	-	-	-	-	554	28
All Others	24	41	27	19	196	8	266	9
Total	2,231	46	2,607	32	2,874	14	2,010	24

Notes: This table includes those cancer deaths that occurred among Wisconsin residents in 1995 that matched a reported cancer diagnosis filed with the Wisconsin Cancer Reporting System since 1978. Each tumor is counted separately for persons with multiple tumors.

See Technical Notes on page 46 for the criteria used to determine a match between incidence and death reports.

Months based on fewer than 20 cases per stage group are omitted because they are subject to large random fluctuations.

Stage of disease for leukemia appears in the "Not Stated" category by default.

See Technical Notes on pages 48-50 for the individual sites included in each major site group.

- C The average number of months to death decreases as stage of disease becomes more advanced: 46 months for cancers diagnosed at local stage, 32 months for cancers diagnosed at regional stage and 14 months for distant-staged cancers.

**Table 21. Average Months to Death for Cases Diagnosed Since 1978 Linked to a 1995 Reportable Cancer Death by Usual Occupation**

PRIMARY SITE/ CAUSE OF DEATH	OCCUPATIONAL CATEGORY									
	Manager & Professional		Technical & Sales		Production		Farming & Fishing		All Others	
	Deaths	Months	Deaths	Months	Deaths	Months	Deaths	Months	Deaths	Months
Mouth & Pharynx	36	25	37	28	33	55	16	-	98	43
Stomach	44	15	49	20	36	14	4	-	120	13
Colon	130	27	127	36	134	33	30	38	439	31
Rectum & Rectosigmoid Junction	56	34	55	36	50	34	18	-	159	36
Pancreas	67	6	87	8	63	6	10	-	235	7
Other Gastro-intestinal Tract	77	15	87	11	73	10	19	-	251	9
Trachea, Bronchus & Lung	322	15	370	13	400	12	124	14	1,066	12
Other Respiratory	7	-	26	34	36	46	7	-	69	33
Bone & Connective Tissue	14	-	12	-	13	-	5	-	57	26
Melanoma of Skin	24	41	16	-	16	-	6	-	57	42
Breast	183	62	158	51	56	62	1	-	484	66
Cervix Uteri	13	-	19	-	11	-	0	-	46	47
Corpus Uteri	28	46	16	-	9	-	0	-	82	39
Other Female Genital	63	36	59	27	14	-	0	-	160	26
Prostate	100	60	166	52	152	50	50	47	316	56
Other Male Genital	5	-	3	-	2	-	0	-	6	-
Urinary Bladder	44	41	45	46	47	42	17	-	125	49
Kidney & Other Urinary	42	30	28	31	50	32	8	-	124	23
Eye, Brain & Other Nervous System	33	19	36	14	32	19	8	-	144	21
Lymph Nodes	63	35	53	33	41	30	14	-	212	33
Leukemia	92	25	98	24	85	28	15	-	264	30
All Others	68	16	75	10	65	10	15	-	290	10
Total	1,511	30	1,622	28	1,418	27	367	27	4,804	28

Notes: This table includes those cancer deaths that occurred among Wisconsin residents in 1995 that matched a reported cancer diagnosis filed with the Wisconsin Cancer Reporting System since 1978. Each tumor is counted separately for persons with multiple tumors.


Precision production, craft and repair occupations are combined with operators, fabricators and laborers in the "production" category. The "farming and fishing" category includes forestry occupations. "All Others" includes service occupations, those recorded as retired, student or housewife, decedents who never entered into an occupation, and other and unknown occupations.

See Technical Notes on page 46 for the criteria used to determine a match between incidence and death reports.

Months based on fewer than 20 cases per occupational group are omitted because they are subject to large random fluctuations.


See Technical Notes on pages 48-50 for the individual sites included in each major site group.

Figure 2. Age-Specific Cancer Mortality Rate




- C The cancer mortality rate rises steadily with age. The male mortality rate is consistently higher than the female mortality rate.

**Figure 3. Cancer Incidence and Mortality by Site and Sex**



Source: Wisconsin Cancer Reporting System and Wisconsin resident death certificates.


**Figure 4. Average Years of Potential Life Lost due to Cancer Mortality by Site Group: Males**



Source: Wisconsin resident death certificates

Note: See Technical Notes on page 46 for information on calculating the average years of potential life lost.

**Figure 5. Average Years of Potential Life Lost Due to Cancer Mortality by Site Group: Females**



Source: Wisconsin resident death certificates

Note: See Technical Notes on page 46 for information on calculating the average years of potential life lost.



## Technical Notes

### The Cancer Reporting Statute (s. 255.04)

- (1) Any hospital, as defined under s. 50.33(2), any physician and any laboratory certified under 42 USC 263a shall report information concerning any person diagnosed as having cancer or a precancerous condition to the department as prescribed by the department under sub. (2).
- (2) The department shall prescribe:
  - (a) The form on which the report under sub. (1) shall be submitted.
  - (b) The time schedule under which the report under sub. (1) shall be submitted.
  - (c) The types of cancer and precancerous conditions to be reported under sub. (1).
- (3) Any information reported to the department under sub. (1) or (5) which could identify any individual who is the subject of the report or the person submitting the report shall be confidential and may not be disclosed by the department except to the following:
  - (a) A central tumor registry in another state if the individual who is the subject of the information resides in the other state.
  - (b) A national tumor registry recognized by the department.
- (4) The report of information under sub. (1) or (5) may not be construed as a violation of any person's responsibility for maintaining the confidentiality of patient health care records, as defined under s. 146.81(4).
- (5) The department may, to the extent feasible, collect information related to the occupation of cancer patients in order to fulfill the purpose of s. 250.04 (3)(b)4.

### Administrative Rules: Hospital Cancer Reporting (HSS 124.05 (h))

Every hospital shall report to the department all malignant neoplasms that are diagnosed by the hospital and all malignant neoplasms diagnosed elsewhere if the individual is subsequently admitted to the hospital. The report of each malignant neoplasm shall be made on a form prescribed or approved by the department and shall be submitted to the department within 6 months after the diagnosis is made or within 6 months after the individual's first admission to the hospital if the neoplasm is diagnosed elsewhere, as appropriate. In this paragraph, "malignant neoplasm" means an in situ or invasive tumor of the human body, but does not include a squamous cell carcinoma or basal cell carcinoma arising in the skin.

NEOPLASM REPORT/RECORD FORM (for 1995)

Hospitals: Complete one form for each new cancer patient admitted. Physicians and clinics: Complete one form for each new cancer patient treated, or for each diagnosed cancer which was not treated if the patient has not been reported by a Wisconsin hospital. Please answer all questions. Enter correct data or circle appropriate number. Throughout this form "reporting agent" refers to the hospital, clinic or physician in item 6. Send the white copy to the address below and retain the yellow copy for your files.

Cancer Reporting System  
Center for Health Statistics--Room 172  
P.O. Box 309  
Madison WI 53701-0309  
Telephone (608)266-8926

1 Patient Last Name		First Name	Middle Name	2 Maiden name, if applicable		3 Sex M Male O Other F Female	
4 Patient Residence Street Address				City	State	Zip Code	5 County
6 Reporting agent. Circle category and write number or name. H Hospital C Clinic Name of hospital, clinic or physician				8 Patient Race / Ethnic Group C Caucasian B Black I American Indian A Asian/Pacific Islander (origin): N Hispanic (origin): O Other (specify): U Unknown			
7 Patient identifier(s) used by reporting agent 1 Tumor Registry Accession Number 2 Medical Record Number 3 Other Identification Specify type of identifier:				9 Birth date M O - D A - Y E A R		10 Marital Status S Single (never married) M Married D Divorced W Widowed U Unknown	
12 Date of first contact w/patient for this cancer M O - D A - Y R		13 Associated discharge date (if #12 overnight adm) M O - D A - Y R		14 Follow-up Physician: Wisconsin license number Physician's Name if number not available:			
15 Date of first diagnosis of this cancer as probable cancer by any recognized physician M O - D A - Y R		16 The diagnosis in #15 was made by: A Reporting agent O Other (specify):		17 Was patient hospitalized previously elsewhere for this cancer? Y Yes (specify where): N No U Unknown			
18 Did the reporting agent refer the patient elsewhere? Y Yes (specify where): N No U Unknown		19 Primary site with subsite. Laterality R Right L Left B Bilateral D One side only U Unknown N Not a paired site		20 Cell type (histology). If unknown, please state.			
21 Diagnostic confirmation. Circle all that apply. 1 Positive histology 2 Positive exfoliative cytology 3 Positive microscopic confirmation (method unknown) 4 Positive laboratory test/marker study 5 Surgical observation 6 X-ray or other imaging techniques 7 Other clinical methods 8 Autopsy 9 Unknown				22 Extent of disease at first occurrence (not recurrence) 1 In situ 2 Localized (entirely confined to organ of origin) 3 Direct extension (into surrounding tissue) 4 Nodes only (metastasis into regional nodes only) 5 Direct extension and nodes (both 3 & 4) 6 Regional, not otherwise specified 7 Distant (spread to tissue/organs remote from origin) 8 Non-localized, not otherwise specified 9 Unknown			
GRADE: 1 Grade I (Well diff.) 2 Grade II (Mod. diff.) 3 Grade III (Poorly diff.) 4 Grade IV (Undiff.) 5 Not determined, not stated, not applicable				TUMOR SIZE at diagnosis (in millimeters) 0 None 1 Peritoneum 2 Lung 3 Pleura 4 Liver 5 Bone 6 Central Nervous System 7 Skin 8 Distant Lymph Nodes 9 Other, Unknown			
23 Definitive therapy provided by reporting agent: treatments that remove or destroy cancer tissue for prolongation of life. Circle all that apply. 1 Surgery 2 Chemotherapy 3 Hormone therapy 4 Endocrine surgery 5 Immunotherapy/BRN 6 Radiation 7 Other (specify):				If NO definitive therapy was provided by the reporting agent, circle one below: A Diagnostic procedure, with or without non-definitive therapy B Non-definitive (palliative) therapy only (those therapies which have no effect on tissue, done to alleviate pain, reduce symptoms, etc.) C No treatment initiated			
24 Date of first definitive therapy provided by reporting agent. Code 000000 if none. M O - D A - Y R							

### Cancer Reporting System Operating Procedures

**Data collection.** The Cancer Reporting System receives its hospital information from medical records departments or tumor registries. Each registry or records department has two major responsibilities in the flow of information. The first is case finding. All of the hospital's newly diagnosed and/or admitted cancer cases need to be identified. As part of this identification, medical records as well as radiology, pathology, outpatient clinic and autopsy reports are examined to assure complete reporting. The second responsibility of the registry or records department is completion of the one-page Neoplasm Report Form, which contains demographic, diagnostic and treatment questions (see previous page). Hospitals with computerized medical records or tumor registries participate by sending computer disks.

Physicians and free-standing clinics report (1) all cancer cases that they treat, and (2) those cases they diagnose if they are not referred to a Wisconsin hospital for treatment within two months of the diagnosis (this accounted for 1,908 cases that were not reported by any other source).

Reports for Wisconsin residents receiving care in Iowa, Illinois, Michigan, California, Indiana, Missouri, Texas, Mississippi, Colorado and Wyoming are provided by the central registries for those states. Minnesota hospitals with substantial numbers of Wisconsin resident cancer patients report Wisconsin cases directly to the Cancer Reporting System.

Finally, the records of the Cancer Reporting System are matched by computer to Wisconsin resident death certificates to add mortality information for persons who have been reported to the Cancer Reporting System and have died. The medical source listed on the death certificate (the hospital, out-of-state registry or physician who certified the death) is asked to confirm and provide information about cancer indicated on the death certificate, but not previously reported to the Cancer Reporting System.

**Reportable Cases.** All primary malignant neoplasms are reportable except basal cell and squamous cell carcinoma of the skin. Benign tumors, premalignant conditions and diseases secondary to the neoplastic process are not reportable.

The 1995 incidence tables are based on Wisconsin resident cases of reportable cancer first diagnosed during 1995 and reported to the Cancer Reporting System by May 1997. This report includes cases reported by Wisconsin hospitals, cooperating out-of-state registries for Wisconsin residents, free-standing clinics and physicians who treat cancer patients, participating Minnesota facilities, and physicians and other health care personnel who responded to the death certificate confirmation survey. **Cancer in Wisconsin, 1995** includes 455 cases originally diagnosed during 1995 that were found through the death certificate confirmation process. Data supplied solely by Minnesota facilities and out-of-state registries accounted for 2.3 percent of all reported cases (577 cases).

**Data Quality.** Cancer reports are routinely edited for completeness and logical consistency, and periodic checks are made for consistency among multiple reports received for the same case. If a problem is found, queries are returned to the reporting agent and corrections are made in the records. For cases for which more than one report is on file, all records are evaluated to determine the best codes for histological description of tumor type, stage of disease at diagnosis, method of diagnostic confirmation, types of definitive therapy and race of patient.

When there are apparent multiple neoplasms of the same primary site, simultaneously or over a period of time, the following rules are used to determine whether more than one independent primary neoplasm exists:

- 1) A single lesion with multiple histologic types is considered a single primary.
- 2) An independent primary cancer of the same histologic type as one diagnosed in the same site more than one year earlier is considered a separate primary. This change does not severely affect the comparability of this year's data with data from past years.
- 3) Simultaneous multiple lesions of the same histologic type within the same primary site are considered a single primary.
- 4) Multiple lesions of different histologic types within a single site, whether occurring simultaneously or at different times, are considered separate primaries.
- 5) Each side of a paired organ is considered a separate site with the following three exceptions: simultaneous ovarian tumors, simultaneous Wilm's tumors (of the kidney) and simultaneous retinoblastomas (of the eye). These exceptions are coded as bilateral tumors of the paired organ (involvement of the tumor in both sides of a paired organ). Aside from the above exceptions, lesions in both sides of a paired organ are considered separate tumors whether occurring simultaneously or at different times unless a physician determines one side is metastatic from the other or the tumor is bilateral.

The incident tumors are classified according to the **International Classification of Diseases for Oncology, Second Edition**. The **Cancer in Wisconsin** reports began using this edition with **Cancer in Wisconsin, 1992**. For code groupings used in the tables, see "Coding of Reported Cases: ICD-O-2 Site Codes" and "Coding of Reported Cases: ICD-O Cell Type Codes" on pages 48-51. The tumor codes in the Mortality and Health Care sections are classified using the **International Classification of Diseases, 1975 Revision**.<sup>6</sup> Throughout this report, site groupings are listed in ICD-9 sequence. Specific ICD-9 codes for the respective site groups are listed on page 52.

While the ICD-O-2 assigns both a primary site code *and* a cell type code to every tumor, ICD-9 codes reflect either site *or* cell type. The ICD-9 has two skin tumor classifications, one for melanomas of the skin and one for all other skin tumors combined. Basal cell and squamous cell carcinoma of the skin, which are not reportable to the Cancer Reporting System, make up the majority of these 'other' skin tumors. Since the ICD-9 classification does not allow for a distinction between the basal cell and squamous cell skin cancers from the other nonmelanoma skin cancers, only melanomas are included in the Mortality section. Reportable nonmelanoma skin cancers are included in the incidence tables in the site group "All Others." In 1995, 98 reportable cases of nonmelanoma skin cancer were diagnosed.

**Completeness of Data.** Cancer Reporting System records include most, but not all, reportable cancer cases involving Wisconsin residents. The 1995 data are estimated to be 95 percent complete (meeting national standards). This percentage should increase over the next five years

due to the statewide training sessions offered to the reporting facilities that focused on decreasing the occurrence of incomplete casefinding, periodic late reporting, and noncompliance.

### Modifications Affecting 1995 Data

**Case Coverage.** Several Minnesota facilities which diagnose and/or treat Wisconsin resident cancer cases began reporting those cases directly to the Cancer Reporting System in 1992. These Minnesota reports improve the completeness of data for the sparsely populated Wisconsin counties along the Minnesota border.

Statewide training sessions on timeliness, completeness and data quality commenced in 1995. The target group for these sessions was cancer reporters from the nearly 300 Wisconsin facilities (hospitals and clinics) that currently report cancer data to CRS. Increased awareness of casefinding techniques may have had some impact on the number of reports submitted to CRS.

**Newly Required and Modified Data Items.** New federally mandated data items were required for data collection starting with 1995 cases. These items are laterality (determines the side of a paired organ where the tumor originated), grade of the cell type (determines the tumor cell's resemblance to normal tissue), tumor size, and site of distant metastases. Laterality is used to determine multiple primaries for paired organs (see Data Quality, page 42).

Modified data items include expanded race/ethnicity codes, clarified marital status (replaced 'not currently married' with 'divorced' or 'widowed'), and longest held occupation and industry. These items have not been collected long enough for a complete presentation or analysis.

### Patient Residence

Tables 4-7 are based on the patient's residence at the time of diagnosis. Tables 16 and 17 are based on the patient's residence at the time of death. The Cancer Reporting System collects postal zip code and county for cancer cases rather than minor civil division of residence (village, town or city). For Table 7, zip codes and county boundaries are used to approximate city of residence. Boundaries used to define city of residence are available upon request.

Two factors should be considered in interpreting the patient residence tabulations. The first is the problem of "small numbers." Many counties have a very small number of new cancer diagnoses or deaths in a year, resulting in a number of site-specific frequencies in the single digits. Such small numbers easily double or triple (or reduce by equivalent amounts) from year to year. When groups of related counties or primary sites are combined, the counts become more stable. Even at the statewide level, however, some random fluctuation is expected. Second, reporting completeness may vary by region. The most serious problem occurs with out-of-state diagnosis and treatment of patients who live in the sparsely-populated counties along the Wisconsin/Minnesota border and are seen by Minnesota hospitals. The inclusion of reports from nearby Minnesota hospitals, starting in 1992, reduced this problem. While two percent of all 1995 cases were reported by Minnesota facilities, the effect in the border counties is quite large. The contribution of Minnesota reports to county incidence is as follows: Douglas (77%), St. Croix (53%), Pierce (44%), Polk (42%), Burnett (40%), Bayfield (38%), Sawyer (28%),

Washburn (28%), Iron (24%), Ashland (20%), Buffalo (19%), Pepin (18%) and Barron (6%). Also, a lag in reporting by an individual hospital can result in local under-reporting of cases, but the effect on regional totals is usually minimal.

### Patient Race

Tables 3, 15 and 18 present cancer information by race. In 1995, 350 reportable cancer deaths involved African Americans and 72 deaths involved people classified as other than white or African American. Reporting of racial and ethnic data is nearly complete on death certificates. However, differences among facilities in recording patient race and ethnicity lead to a large number of "other and unknown" codes for the incidence case reports. These differences include the method of collection and the categories used to determine race and ethnicity. The 561 "other and unknown" cases in 1995 represent a combination of uncoded, ambiguously coded, and other nonwhite and non-African American racial and ethnic cases. Extensive training and expanded race codes implemented for 1995 cases should start to increase the percentage of correct race reporting for future publications.

### Stage of Disease

The stage of disease reflects the extent to which the disease has spread from the site of origin at the time of diagnosis. The following definitions are used in assigning a stage to each neoplasm.

*In Situ* - A malignant noninvasive tumor (involves only the cells in which the cancer began).

*Localized* - An invasive malignant tumor that appears to be confined entirely to the organ of origin.

*Regional* - A tumor that has extended beyond the limits of the organ of origin into (1) surrounding organs or tissues by direct extension, (2) regional lymph nodes by metastasis, or (3) a combination of (1) and (2), and appears to have spread no further.

*Distant* - A tumor that has spread to parts of the body remote from the primary organ.

*Non-localized, Not Otherwise Specified* - A neoplasm that has extended beyond "localized" but for which a precise stage cannot be determined. This category includes systemic cancers; it is the default for leukemias.

### Type of Diagnostic Confirmation

The type of diagnostic confirmation reported indicates the method used to provide the most accurate evidence for the diagnosis of cancer. Microscopic confirmation is required to identify cell type, the most sensitive measure of the *type* of cancer. The following definitions and examples are used in coding diagnostic confirmation.

*Positive Histology* - Microscopic diagnosis based upon specimen from a biopsy or frozen section

of tissue.

*Positive Cytology or Blood Confirmation* - Diagnosis based upon microscopic examination of cells (as opposed to tissue).

*Positive Microscopic Confirmation, Not Otherwise Specified* - Microscopic diagnosis with the method unspecified.

*Laboratory Test/Marker Study* - Clinical diagnosis based on a laboratory test or a tumor marker study.

*Surgery Observation Without Microscopic Confirmation* - Diagnosis made on the basis of visualization or palpation during surgery.

*Imaging* - Includes chest films, bone series, mammograms, angiograms, upper g.i. series, etc.

*Other Clinical Methods* - Diagnosis based on medical history, physical examination and other clinical methods not mentioned above.

*Autopsy* - Reported when the cancer is first discovered or confirmed upon autopsy. An autopsy may involve microscopic examination of tissues or cells.

## Treatment Modality

Cancer patients may receive definitive therapy (directed toward reduction or elimination of cancer cells) or nondefinitive therapy (directed toward better functioning or improved patient comfort but not affecting the growth of cancer cells). Definitive therapy may be administered through one or more treatment modalities. Table 12 distinguishes between definitive and nondefinitive therapies (included in the 'no cancer-directed treatment' column) while Table 13 presents modalities solely from definitive therapy. Nonsurgical definitive therapy performed to augment surgery is often called "adjuvant" therapy. Some cancers are treated entirely with nonsurgical therapy.

The following is tabulated as "surgical treatment":

*Surgery* - An operative procedure performed to remove cancer tissue, even if the cancer tissue is known not to be entirely removed. A biopsy performed to identify the cell type of the tumor is surgical treatment only if it removes the entire tumor (excisional biopsy).

The following are tabulated as "nonsurgical treatment":

*Laser Surgery* - Destruction of cancer tissue with a laser beam, most commonly used for vaginal or oral tumors.

*Cryosurgery* - Destruction of cancer cells by freezing the cells. Cold conization of a cervical tumor is the most frequent use.

*Chemosurgery* - Direct application of a chemical to a surface, generally a skin surface, to destroy cancer tissue.

*Chemotherapy* - Use of chemicals and drugs to destroy cancer cells and tissue.

*Hormone Therapy* - Administration of hormones to stop the growth of cancer cells, often given in combination with chemotherapy.

*Endocrine Surgery* - Removal of an endocrine gland to stop growth of a cancer in another organ, when the hormonal product of the endocrine gland is implicated in the growth of the tumor.

*Immunotherapy* - Stimulation of the body's natural mechanisms for biochemically attacking foreign cells and substances.

*Radiation* - Use of external beams or internal radioactive implants independently or before, during or after surgery to kill tumor cells.

*Other* - Any generally accepted or experimental cancer-directed treatment modality not listed above.

The Cancer Reporting System collects information only about “facility-specific” treatment (treatment *performed* by the reporting facility). Due to the Cancer Reporting System’s wide base of reporting facilities and the guidelines for reporting, most treatments do get reported, even if not all are performed at the same facility (many patients receive treatment for their cancer from different facilities). Consequently, many reports may be received by the Cancer Reporting System for the same tumor. Data in Tables 12 and 13 are compiled from the cumulative reports for cases diagnosed in 1995 and reported by May 1997 and, consequently, represent an approximation of "first course" (planned) treatment. Treatment data may also include subsequent treatments from recurrence of the tumor.

### **Incidence/Death Case Matching**

The underlying cause of death is the disease or injury which initiated the chain of morbid events leading directly to death or the circumstances of the accident or violence that produced the fatal injury. The underlying cause of death in the mortality tables in this publication is a reportable cancer.

Tables 19-21 are derived from incidence records updated with death information. Death is presumed to be caused by a given reported tumor under the following circumstances: when the ICD-O site and cell type codes and the ICD-9 underlying cause of death code agree exactly in designation of primary site or cell type; when the ICD-9 code is a broad one which subsumes the ICD-O code; when the ICD-O code subsumes the cause of death code; or when the two designate adjacent organs. If more than one primary tumor for the same person fits the ICD-9 designation, the tumor which fits best is assumed to be the tumor which caused death.

### Years of Life Lost

The years of life lost for an individual cancer patient who dies as a result of cancer is the difference between that individual's age at death and the expected age at death for a person of the same sex having reached the same age. The average years of life lost by sex and primary site group is the sum, respectively, of years lost by all individuals of each sex who died due to cancer of each primary site, divided by the actual number of deaths for that primary site and sex. The expected age at death for **Cancer in Wisconsin, 1995** is calculated from the Wisconsin life tables for 1993-95. The life tables used to calculate the potential average years of life lost for **Cancer in Wisconsin** reports has varied, and documentation for each publication should be consulted before comparing data.

### Comparing Cancer Data

**Rates.** Crude rates, or overall rates, are the total number of newly-diagnosed cancer cases or deaths due to cancer per 100,000 persons in the total population. Crude rates are useful for evaluating the level of resources needed to treat cancer. However, when comparing rates over time or across different populations, crude rates can be misleading because differences in the age distributions of the various populations are not considered. Cancer is age-dependent, so the comparison of crude rates of cancer can be especially misleading. Crude rates are not reported in any of the **Cancer in Wisconsin** tables. Both crude and age-specific rates can be calculated from the population tables on pages 53-54. The 1995 age-specific rates in Figures 1 and 2 are the number of events per 100,000 persons in each five-year age range, based on Table 8 and comparable mortality data.

Age-adjusted rates take into account the diverse age distributions between populations. Valid comparisons between age-adjusted rates can be made, provided the same standard population and age groups have been used in the calculation of the rates. The direct method of adjustment was used to produce the age-adjusted rates for this report. The population is divided into reasonably homogeneous age ranges. The age-specific rate is calculated for each age range, then each age-specific rate is weighted by multiplying it by the proportion of the 1970 United States standard population in the respective age group. The age-adjusted rate is the sum of the weighted age-specific rates.

All age-adjusted rates in **Cancer in Wisconsin, 1995** were calculated using five-year age intervals. The methodology used to calculate age-adjusted rates for **Cancer in Wisconsin** reports has varied, and documentation for each publication should be consulted before comparing published rates.

**Stage of disease.** Readers are cautioned when comparing in situ cervical cancer data over a wide range of years because of past technological changes in cytologic and pathologic classifications of pre-invasive cervical cancers. In particular, classification systems which formerly distinguished between noninvasive malignant lesions and noninvasive pre-malignant or benign lesions have been combined in newer systems. The effect on the data depends on the use of terminology by cytologists and pathologists. The short-term effects are minimal and these changes have not affected reporting of in situ cancers of other sites.

**Case coverage.** Due to the increase in reporting sources in recent years, readers are reminded to be cautious about comparisons between 1995 data that might be affected by the contribution of newer reporting sources and data for previous years reported in earlier publications.

**DHFS Regions.** This report reflects new Department of Health and Family Services Regions established as of July 1, 1996 (see map on page 55). Comparisons with regional data in previous publications may be affected.

### Supplemental Data Sources

Mortality data are obtained from death certificates for Wisconsin residents. The mortality tables are based on deaths occurring in 1995 for which the underlying cause of death was a reportable cancer. Certificates for out-of-state deaths of Wisconsin residents are provided by the states where the deaths occurred. Months between diagnosis and death are calculated from the date of death shown on the death certificate and the date of diagnosis from the case reports.

Wisconsin population estimates were calculated by the Center for Health Statistics. The population estimates used in this report provide the best data known at the statewide level and represent good estimates at the regional level. Because population calculations have been based on different methodologies from year to year, age-adjusted rates based on these estimates are not strictly comparable although in most cases the results will be close.

CODING OF REPORTED CASES  
ICD-O-2 Site Codes (1990 Code Version)

Page 1 of 3

---

PRIMARY SITE NAME	Major Site Group	Site Group	Individual Site
Lip			C00
Tongue		C01 - C02	
Major Salivary Glands			C07 - C08
Gum			C03
Floor of Mouth			C04
Other & Unspecified Parts of Mouth			C05 - C06
Oropharynx			C09 - C10
Nasopharynx			C11
Hypopharynx			C12 - C13
Other Sites in Lip, Oral Cavity, & Pharynx			C14
Mouth and Pharynx		C00 - C14	
Esophagus			C15
Stomach			C16
C16			
Small Intestine			C17
Colon		C18	C18
Rectum, Rectosigmoid Junction, & Anus		C19 - C21	C19 - C21
Colorectal		C18 - C21	
Liver & Intrahepatic Bile Ducts			C22
Gallbladder & Extrahepatic Bile Ducts			C23 - C24
Pancreas		C25	C25
Retroperitoneum & Peritoneum			C48
Other Within Digestive Organs & Peritoneum			C26
Other Gastro-intestinal Tract		C15, C17, C22 - C24	
		C26, C48	
Gastro-intestinal Tract		C15 - C17	
		C22 - C26, C48	
Nasal Cavities & Sinuses, Internal Ear			C30 - C31
Larynx			C32
Trachea, Bronchus, & Lung		C33 - C34	C33 - C34
Pleura			C38*
Thymus, Heart, & Mediastinum			C37 - C38*
Other Respiratory & Intrathoracic Sites			C39
Other Respiratory		C30 - C32	
		C37 - C39	
Respiratory		C30 - C39	

---

\*Pleura sites are coded C38.4; heart and mediastinum sites are identified by the other C38.x codes

CODING OF REPORTED CASES  
ICD-O-2 Site Codes (1990 Code Version)

Page 2 of 3

PRIMARY SITE NAME	Major Site Group	Site Group	Individual Site
Hematopoietic & Reticuloendothelial Systems, Except Leukemia			C42
Bone, Joints, & Articular Cartilage			C40 - C41
Connective, Subcutaneous, Other Soft Tissue			C47, C49
Bone & Connective Tissue			C40 - C41
			C47, C49
Melanoma of Skin			Site code C44 if also Cell Type Code 872 - 879
Breast	C50	C50	C50
Uterus, NOS			C55
Cervix Uteri		C53	C53
Placenta			C58
Corpus Uteri		C54	C54
Ovary, Fallopian Tube, & Broad Ligament			C56 - C57*
Other & Unspecified Female Genital Organs			C51 - C52, C57*
Other Female Genital			C51 - C52
			C55 - C58
Female Genital			C51 - C58
Prostate		C61	C61
Testis			C62
Penis & Other Male Genital Organs			C60, C63
Other Male Genital			C60, C62 - C63
Male Genital			C60 - C63
Urinary Bladder		C67	C67
Kidney & Other Urinary Organs		C64 - C66, C68	C64 - C66, C68
Urinary Tract			C64 - C68
Eye & Lacrimal Gland			C69
Brain			C71
Other & Unspecified Parts of Nervous System			C70, C72
Eye, Brain & Other Nervous System			C69 - C72
Thyroid Gland			C73
Other Endocrine Glands			C74 - C75

\*Broad ligament and ovary sites are coded C57.0 and C57.1, respectively; "other and unspecified female genital" sites are the remaining C57.x codes

CODING OF REPORTED CASES  
ICD-O-2 Site Codes (1990 Code Version)

Page 3 of 3

PRIMARY SITE NAME	Major Site Group	Site Group	Individual Site
Lymph Nodes .....		C77	C77, Except Cell Type Code 965 - 966
Hodgkin's Disease .....			Cell Type Code 965 - 966
Lymphoid Leukemia .....			Cell Type Code 982
Myeloid Leukemia .....			Cell Type Code 986
Other Leukemia .....			Cell Type Code 980, 981 983 - 985, 987 - 994
Leukemia .....			Cell Type Code 980 - 994
Leukemia & Lymph Nodes .....			Cell Type Code 980 - 994 plus Site Code C77
Other & Ill-defined Sites (Includes Reportable Nonmelanoma Skin Sites) .....			C44, C76
All Other (Includes Reportable Nonmelanoma Skin Sites, Endocrine, Nonleukemic Hematopoietic & Reticuloendothelial Sites and Ill-Defined and Unknown Sites) .....			C42, C44 C73 - C76 C80
All Others (Includes Mouth & Pharynx, Reportable Nonmelanoma Skin Sites, Endocrine, Nonleukemic Hematopoietic & Reticuloendothelial Sites, Eye, Brain and Central Nervous System Sites and Ill-Defined and Unknown Sites) .....			C00 - C14 C40 - C44, C47 C49, C69 - C76 C80
Unknown Primary Site .....			C80

Note: Basal and squamous cell carcinoma of skin sites and nonmalignant neoplasms are not reportable. Extra-nodal lymphomas are coded to their respective primary sites rather than to lymph nodes.

CODING OF REPORTED CASES  
ICD-O Cell Type Codes (Encompasses 1976 and 1990 Code Versions)

CELL TYPE GROUP	CODE
Small Cell/Oat Cell Carcinoma . . . . .	804
Squamous Cell Carcinoma . . . . .	807
Transitional Cell Carcinoma . . . . .	812
Papillary Transitional Cell Carcinoma . . . . .	813
Papillary Adenocarcinoma . . . . .	826
Clear, Renal & Granular Cell Adenocarcinoma . . . . .	831-832
Cystadenocarcinoma . . . . .	844-847
Mucinous Adenocarcinoma . . . . .	848
Ductal Adenocarcinoma . . . . .	850
Medullary Adenocarcinoma . . . . .	851
Lobular Adenocarcinoma . . . . .	852
Other Specified Adenocarcinoma . . . . .	815-820, 823-825 827-830, 833-838 840-842, 855
Other Adenocarcinoma . . . . .	849, 853, 854
Adenocarcinoma, NOS . . . . .	814, 821, 822
Carcinoma, Not Otherwise Specified (NOS) . . . . .	801-802
Sarcoma, NOS and Osteogenic Sarcoma . . . . .	880, 918, 919
Astrocytoma, NOS . . . . .	940
Glioblastoma Multiforme . . . . .	944
Germ Cell Neoplasms . . . . .	906-909
Hodgkin's Disease . . . . .	965-966
Non-Hodgkin's Lymphoma . . . . .	959-964, 967-970, 975
Lymphoid Leukemia . . . . .	982
Myeloid Leukemia . . . . .	986
Other Leukemia . . . . .	980-981, 983-985 987-994
Plasma Cell Tumors . . . . .	973
Unknown Cell Type . . . . . (Includes "No Microscopic Confirmation")	800, 999
All Others . . . . .	803, 805, 808-811 839, 843, 856-879 881-905, 910-917 922-939, 941-943 945-958, 972, 974, 976

CODING OF MORTALITY  
ICD-9 Cancer Codes

PRIMARY SITE NAME	Major Site Group	Site Group
Mouth and Pharynx . . . . .		140 - 149
Stomach . . . . .		151
Colon . . . . .		153
Rectum, Rectosigmoid Junction, & Anus . . . . .		154
Colorectal . . . . .	153, 154	
Pancreas . . . . .		157
Other Gastro-intestinal Tract . . . . .		150, 152, 155
. . . . .		156, 158, 159
Other Gastro-intestinal Tract . . . . .	150 - 152	
. . . . .	155 - 159	
Trachea, Bronchus & Lung . . . . .		162
Other Respiratory . . . . .		160 - 161
. . . . .		163 - 165
Respiratory . . . . .	160 - 165	
Bone & Connective Tissue . . . . .		170, 171
Melanoma of Skin . . . . .		172
Breast . . . . .	174 - 175	174 - 175
Cervix Uteri . . . . .		180
Body of Uterus . . . . .		182
Other Female Genital . . . . .		179, 181
. . . . .		183, 184
Female Genital . . . . .	179 - 184	
Prostate . . . . .		185
Other Male Genital . . . . .		186 - 187
Male Genital . . . . .	185 - 187	
Urinary Bladder . . . . .		188
Kidney, Other, & Unspecified Urinary Organs . . . . .		189
Urinary Tract . . . . .	188 - 189	
Eye, Brain & Other Nervous System . . . . .		190 - 192
Lymphoma . . . . .		200 - 202
Leukemia . . . . .		204 - 208
Lymphoma & Leukemia . . . . .	200 - 202	
. . . . .	204 - 208	
All Others . . . . .		193 - 195, 199, 203
All Others . . . . .	140 - 149, 170 - 172	
. . . . .	190 - 195, 199, 203	

WISCONSIN POPULATION ESTIMATES BY AGE AND SEX  
July 1, 1995

---


Age	Male	Female	Total
ALL AGES	2,513,540	2,605,700	5,119,240
UNDER 5	175,970	167,730	343,700
5-9	193,450	184,380	377,830
10-14	204,990	193,640	398,630
15-19	191,480	183,250	374,730
20-24	169,380	167,640	337,020
25-29	175,060	176,480	351,540
30-34	203,640	204,320	407,960
35-39	219,400	215,510	434,910
40-44	201,550	198,860	400,410
45-49	167,490	169,880	337,370
50-54	128,330	131,490	259,820
55-59	105,490	110,260	215,750
60-64	95,960	101,680	197,640
65-69	90,140	102,540	192,680
70-74	75,890	94,040	169,930
75-79	56,710	81,800	138,510
80-84	35,230	61,980	97,210
85+	23,380	60,220	83,600

---

WISCONSIN COUNTY POPULATION ESTIMATES  
July 1, 1995

County	Population	County	Population
Adams	17,090	Marinette	41,960
Ashland	16,580	Marquette	13,420
Barron	42,180	Menominee	4,310
Bayfield	14,530	Milwaukee	952,150
Brown	210,400	Monroe	38,270
Buffalo	13,700	Oconto	31,990
Burnett	13,830	Oneida	34,080
Calumet	37,150	Outagamie	150,850
Chippewa	53,950	Ozaukee	78,440
Clark	32,390	Pepin	7,180
Columbia	48,010	Pierce	34,050
Crawford	16,210	Polk	36,520
Dane	394,200	Portage	65,200
Dodge	80,090	Price	16,010
Door	26,290	Racine	183,630
Douglas	42,510	Richland	17,610
Dunn	37,630	Rock	146,920
Eau Claire	88,230	Rusk	15,250
Florence	4,970	St Croix	54,060
Fond du Lac	93,780	Sauk	50,700
Forest	9,120	Sawyer	15,140
Grant	49,430	Shawano	38,160
Green	31,620	Sheboygan	108,370
Green Lake	19,140	Taylor	19,210
Iowa	21,380	Trempealeau	25,810
Iron	6,300	Vernon	26,420
Jackson	17,120	Vilas	19,300
Jefferson	71,980	Walworth	81,100
Juneau	22,980	Washburn	14,590
Kenosha	138,290	Washington	108,570
Kewaunee	19,380	Waukesha	332,940
La Crosse	102,430	Waupaca	48,830
Lafayette	16,210	Waushara	20,420
Langlade	20,290	Winnebago	148,630
Lincoln	28,480	Wood	76,180
Manitowoc	82,890		
Marathon	122,210	STATE TOTAL	5,119,240

## Department of Health and Family Services Regions



**Age-Adjusted Rate of Reported Cancer Cases for 1993 Diagnoses by Site Group and Sex, Updated to Include All Cases Reported by May 1997**

PRIMARY SITE	MALE		FEMALE		TOTAL	
	Number	Rate	Number	Rate	Number	Rate
Mouth & Pharynx	383	15.1	184	5.6	567	10.0
Stomach	268	9.9	159	4.0	427	6.6
Colon	1,237	46.1	1,180	31.3	2,417	37.6
Rectum & Rectosigmoid Junction	503	19.0	409	11.6	912	14.9
Pancreas	262	10.0	264	7.1	526	8.5
Other Gastro-intestinal Tract	462	17.6	317	9.2	779	13.0
Trachea, Bronchus & Lung	1,951	74.8	1,185	37.3	3,136	53.7
Other Respiratory	318	12.4	83	2.8	401	7.2
Bone & Connective Tissue	144	5.5	116	4.0	260	4.6
Melanoma of Skin	264	9.9	237	7.5	501	8.5
Breast	20	0.7	3,775	120.4	3,795	64.8
Cervix Uteri	-	-	978	33.7	978	17.1
Corpus Uteri	-	-	644	21.3	644	11.4
Other Female Genital	-	-	777	24.2	777	13.0
Prostate	4,166	155.6	-	-	4,166	67.5
Other Male Genital	202	7.0	-	-	202	3.4
Urinary Bladder	833	31.2	315	8.7	1,148	18.4
Kidney & Other Urinary	370	14.2	216	6.8	586	10.1
Eye, Brain & Other Nervous System	249	9.5	200	6.8	449	8.1
Lymph Nodes	460	17.5	384	11.9	844	14.5
Leukemia	394	14.8	325	9.6	719	11.9
All Others	538	19.8	690	20.0	1,228	19.6
All Reportable Sites	13,024	490.7	12,438	383.8	25,462	424.3

Notes: Data in this table represent cases diagnosed in 1993 and reported to the Cancer Reporting System by May 1997, the date of compilation for **Cancer in Wisconsin, 1995**. This table is comparable to Table 1 in **Cancer in Wisconsin, 1993** (22,801 total cases reported with the total age-adjusted rate of 377.8).

Rates are per 100,000 residents, age-adjusted to the 1970 United States population.

- C Cancer in Wisconsin is a 'point in time' publication that represents the number of reports received by a pre-determined 'cut-off' date. Every effort is made to produce the report shortly after the required due date for each year's cases. However, some cases are not reported until after the data are compiled. Various reasons include care patterns (a patient may not have been cared for by a CRS reporting facility until some time after initial diagnosis), interstate data exchange (delays occur in the transferring of data between central registries due to data processing) and facility lapses in casefinding and timeliness of reporting. Reports for cases diagnosed in a given year continue to accumulate for two to three years after the due date for that diagnosis year.